

(19)



Eur päisch e Pat ntamt  
European Patent Office  
Offi e européen des brevets



(11)

EP 0 369 817 B1

(12)

# EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
24.04.1996 Bulletin 1996/17

(51) Int Cl. C12N 15/57, C12N 15/31,  
C12N 9/56, C12P 21/02

(21) Application number: 89311950.3

(22) Date of filing: 17.11.1989

(54) **Bacillus strains**

Bacillus-Stämme

Souches de bacillus

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(30) Priority: 18.11.1988 US 273423  
04.05.1989 US 347428  
21.08.1989 US 396521

(43) Date of publication of application:  
23.05.1990 Bulletin 1990/21

(73) Proprietor: OMNIGENE BIOPRODUCTS, INC.  
Cambridge, Massachusetts 02139-9002 (US)

(72) Inventors:

- Sloma, Alan  
Watertown, MA 02172 (US)
- Rudolf, Cathy Faye  
Stoughton, MA 02072 (US)
- Pero, Janice  
Lexington, MA 02173 (US)
- Rufo, Gerald A.  
Burlington, MA 01830 (US)
- Sullivan, Barbara J.  
Burlington, MA 01803 (US)

(74) Representative: Deans, Michael John Percy et al  
Lloyd Wise, Tregear & Co.,  
Commonwealth House,  
1-19 New Oxford Street  
London WC1A 1LW (GB)

(56) References cited:  
WO-A-86/01825

- JOURNAL OF BACTERIOLOGY, vol. 160, no. 1,  
October 1984, Baltimore, MD (US); F.  
KAWAMURA et al., pp. 442-444
- JOURNAL OF BACTERIOLOGY, vol. 167, no. 1,  
July 1986, Baltimore, MD (US); Y. KOIDE et al.,  
pp. 110-116
- JOURNAL OF BACTERIOLOGY, vol. 170, no. 1,  
October 1988, Baltimore, MD (US); B. BEALL et  
al., pp. 4855-4864
- GENE, vol. 70, no. 2, 30 October 1988,  
Amsterdam (NL); H. SMITH et al., pp. 351-361
- JOURNAL OF BACTERIOLOGY, vol. 170, no. 12,  
December 1988, Baltimore, MD (US); A. SLOMA  
et al., pp. 5557-5563
- JOURNAL OF BACTERIOLOGY, vol. 172, no. 3,  
March 1990, Baltimore, MD (US); A. SLOMA et al.,  
pp. 1470-1477
- JOURNAL OF BACTERIOLOGY, vol. 166, no. 1,  
April 1986, Baltimore, MD (US); E. FERRARI et  
al., pp. 173-179

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 369 817 B1

## Description

This invention relates to Bacillus strains. We describe below such strains useful for the expression and secretion of desired polypeptides (as used herein, "polypeptide" means any useful chain of amino acids, including proteins).

Bacillus strains have been used as hosts to express heterologous polypeptides from genetically engineered vectors. The use of a Gram positive host such as Bacillus avoids some of the problems associated with expressing heterologous genes in Gram negative organisms such as E. coli. For example, Gram negative organisms produce endotoxins which may be difficult to separate from a desired product. Furthermore, Gram negative organisms such as E. coli are not easily adapted for the secretion of foreign products, and the recovery of products sequestered within the cells is time-consuming, tedious, and potentially problematic. In addition, Bacillus strains are non-pathogenic and are capable of secreting proteins by well-characterized mechanisms.

A general problem in using Bacillus host strains in expression systems is that they produce large amounts of proteases which can degrade heterologous polypeptides before they can be recovered from the culture media. The proteases which are responsible for the majority of this proteolytic activity are produced at the end of the exponential phase of growth, under conditions of nutrient deprivation, as the cells prepare for sporulation. The two major extracellular proteases are an alkaline serine protease (subtilisin), the product of the apr gene, and a neutral metalloprotease, the product of the npr gene, are secreted into the medium, whereas the major intracellular serine protease, isp-1, is produced within the cells. Other investigators have created genetically altered Bacillus strains that produce below-normal levels of one or more of these three proteases, but these strains still produce high enough levels of protease to cause the degradation of heterologous gene products prior to purification.

Stahl et al. (J. Bact., 1984, 158:411) disclose a Bacillus protease mutant in which the chromosomal subtilisin structural gene was replaced with an in vitro derived deletion mutation. Strains carrying this mutation produced only 10% of the wild-type extracellular serine protease activity. Yang et al. (J. Bact., 1984, 160:15) disclose a Bacillus protease mutant in which the chromosomal neutral protease gene was replaced with a gene having an in vitro derived deletion mutation. Fahnestock et al. (WO 86/01825) describe Bacillus strains lacking subtilisin activity which were constructed by replacing the native chromosomal gene sequence with a partially homologous DNA sequence having an inactivating segment inserted into it. Kawamura et al. (J. Bact., 1984, 160:442) disclose Bacillus strains carrying lesions in the npr and apr genes and expressing less than 4% of the wild-type level of extracellular protease activity. Koide et al. (J. Bact., 1986, 167:110) disclose the cloning and sequencing of the isp-1 gene and the construction of an isp-1 negative mutant by chromosomal integration of an artificially deleted gene.

Genetically altered strains which are deleted for the extracellular protease genes (apr and npr) produce significantly lower levels of protease activity than do wild-type Bacillus strains. These bacteria, when grown on medium containing a protease substrate, exhibit little or no proteolytic activity, as measured by the lack of appearance of a zone of clearing (halo) around the colonies. Some heterologous polypeptides and proteins produced from these double mutants are, nevertheless, substantially degraded prior to purification, although they are more stable than when produced in a wild-type strain of Bacillus.

The invention provides improved Bacillus cells containing mutations in one or more of three previously uncharacterized protease genes; the cells also preferably contain mutations in the apr and npr genes that encode the major extracellular proteases, resulting in the inhibition by the cells of production of these extracellular proteases. The mutations of the invention include a mutation in the apr gene which inhibits the production by the cell of the proteolytically active apr gene product, and/or a mutation in the gene (herein, the "RP-I" gene) encoding residual protease I (RP-I) which inhibits the production by the cell of proteolytically active RP-I, and/or a mutation in the gene (herein, the "RP-II" gene) encoding residual protease II (RP-II). The proteases encoded by the apr gene and RP-II genes are novel proteins. Most preferably, the mutations are deletions within the coding region of the genes, including deletion of the entire coding region; alternatively, a mutation can consist of a substitution of one or more base pairs for naturally occurring base pairs, or an insertion within the protease coding region.

Bacillus cells in accordance with the invention may additionally contain a mutation in the isp-1 gene encoding intracellular serine protease I and may in addition contain a mutation which blocks sporulation and thus reduces the cell's capacity to produce sporulation-dependent proteases; preferably, this mutation blocks sporulation at an early stage but does not eliminate the cell's ability to be transformed by purified DNA; most preferably, this mutation is the spoOA mutation (described below).

The invention provides, in an alternative aspect thereof, a method for producing stable heterologous polypeptides in a Bacillus host cell by modifying the host to contain mutations in the apr and npr genes and in one or more of the genes including the apr gene, the RP-I gene, and the RP-II gene.

The invention also features, in respective further aspects thereof, purified DNA, expression vectors containing DNA, and host Bacillus cells transformed with DNA, in each case encoding one of the proteases RP-I, RP-II, or the product of the apr gene; preferably, such DNA is derived from Bacillus subtilis.

The invention also features, in yet further aspects thereof, the isolation of substantially pure Epr, residual protease

I (RP-I), and another previously uncharacterised protease called residual protease II (RP-II), and characterisation of the RP-I and RP-II proteases; as used herein, "substantially pure" means greater than 90% pure by weight.

The terms "apr gene", "RP-I gene", and "RP-II gene" herein mean the respective genes corresponding to these designations in Bacillus subtilis, and the evolutionary homologues of those genes in other Bacillus species, which homologues, as is the case for other Bacillus proteins, can be expected to vary in minor respects from species to species. The RP-I and RP-II genes of B. subtilis are also designated, respectively, the bpr and mpr genes. In many cases, sequence homology between evolutionary homologues is great enough so that a gene derived from one species can be used as a hybridization probe to obtain the evolutionary homologue from another species, using standard techniques. In addition, of course, those terms also include genes in which base changes have been made which, because of the redundancy of the genetic code, do not change the encoded amino acid residue.

Using the procedures described herein, we have produced Bacillus strains which are significantly reduced in their ability to produce proteases, and are therefore useful as hosts for the expression, without significant degradation, of heterologous polypeptides capable of being secreted into the culture medium. We have found that our Bacillus cells, even though containing several mutations in genes encoding related activities, are not only viable but healthy.

Any desired polypeptide can be expressed using our techniques, e.g., medically useful proteins such as hormones, vaccines, antiviral proteins, antitumor proteins, antibodies or clotting proteins; and agriculturally and industrially useful proteins such as enzymes or pesticides, and any other polypeptide that is unstable in Bacillus hosts that contain one or more of the proteases inhibited in our cells.

Other features and advantages of the invention will be apparent from the following description of preferred embodiments thereof.

The drawings will first be briefly described.

Fig. 1 is a series of diagrammatic representations of the plasmids p371 and p371Δ, which contain a 2.4 kb HindIII insert encoding the Bacillus subtilis neutral protease gene and the same insert with a deletion in the neutral protease gene, respectively, and p371ΔCM, which contains the Bacillus cat gene.

Fig. 2 is a Southern blot of HindIII digested IS75 and IS75Δ DNA probed with a <sup>32</sup>P-labeled oligonucleotide corresponding to part of the nucleotide sequence of the npr gene.

Fig. 3 is a representation of the 6.5 kb insert of plasmid pAS007, which encodes the Bacillus subtilis subtilisin gene, and the construction of the deletion plasmid pAS13.

Fig. 4 is a representation of the plasmid pISP-1 containing a 2.7 kb BamHI insert which encodes the intracellular serine protease ISP-1, and the construction of the ISP-1 deletion plasmid pΔI5.

Fig. 5 is a diagrammatic representation of the cloned apr gene, showing restriction enzyme recognition sites.

Fig. 6 is the DNA sequence of the apr gene.

Fig. 7 is a diagrammatic representation of the construction of the plasmid pNP9, which contains the deleted apr gene and the Bacillus cat gene.

Fig. 8 is the amino acid sequence of the first 28 residues of RP-I and the corresponding DNA sequence of the probe used to clone the RP-I gene.

Fig. 9 is a restriction map of the 6.5kb insert of plasmid pCR83, which encodes the RP-I protease.

Fig. 10 is the DNA sequence of DNA encoding RP-I protease.

Fig. 11 is the amino acid sequence of three internal RP-II fragments (a, b, c), and the nucleotide sequence of three guess-mers used to clone the gene (a), (b) and (c).

Fig. 12 is a Southern blot of GP241 chromosomal DNA probed with BRT90 and 707.

Fig. 13 is a diagram of (a) a restriction map of the 3.6 kb PstI insert of pLPI, (b) the construction of the deleted RP-II gene and (c) the plasmid used to create an RP-II deletion in the Bacillus chromosome.

Fig. 14 is the DNA sequence of DNA encoding RP-II.

#### General Strategy for Creating Protease Deleted Bacillus Strains

The general strategy we followed for creating a Bacillus strain which is substantially devoid of proteolytic activity is outlined below.

A deletion mutant of the two known major extracellular protease genes, apr and npr, was constructed first. The isp-1 gene encoding the major intracellular protease was then deleted to create a triple protease deletion mutant. The spoOA mutation was introduced into either the double or triple deletion mutants to significantly reduce any sporulation dependent protease activity present in the cell. A gene encoding a previously unknown protease was then isolated and its entire nucleotide sequence was determined. The gene, apr, encodes a primary product of 645 amino acids that is partially homologous to both subtilisin (Apr) and the major internal serine protease (Isp-1) of B. subtilis. A deletion of this gene was created *in vitro* and introduced into the triple protease deleted host. A deletion in a newly identified gene encoding residual protease RP-I was then introduced to create a strain of B. subtilis having substantially reduced protease activity and expressing only the RP-II activity. RP-II has been purified and a portion of the amino acid sequence

was determined for use in creating the nucleic acid probes which were used to clone the gene encoding this protease. Upon cloning the gene, it was possible to create a Bacillus strain which contains a deletion in the RP-II gene and is thus incapable of producing RP-II.

Detailed procedures for construction of the protease gene deletions and preparation of Bacillus strains exhibiting reduced protease activity are described below.

#### General Methods

Our methods for the construction of a multiply deleted Bacillus strain are described below. Isolation of B. subtilis chromosomal DNA was as described by Dubnau et al., (1971, J. Mol. Biol., 56: 209). B. subtilis strains were grown on tryptose blood agar base (Difco Laboratories) or minimal glucose medium and were made competent by the procedure of Anagnostopoulos et al., (J. Bact., 1961, 81: 741). E. coli JM107 was grown and made competent by the procedure of Hanahan (J. Mol. Biol., 1983, 166: 587). Plasmid DNA from B. subtilis and E. coli were prepared by the lysis method of Birnboim et al. (Nucl. Acid. Res., 1979, 7: 1513). Plasmid DNA transformation in B. subtilis was performed as described by Gryczan et al., (J. Bact., 1978, 134: 138).

#### Protease assays

Two different protease substrates, azocoll and casein (labelled either with  $^{14}\text{C}$  or the chromophore resorufin), were used for protease assays, with the casein substrate being more sensitive to proteolytic activity. Culture supernatant samples were assayed either 2 or 20 hours into stationary phase. Azocoll-based protease assays were performed by adding 100  $\mu\text{l}$  of culture supernatant to 900  $\mu\text{l}$  of 50 mM Tris, pH 8, 5 mM  $\text{CaCl}_2$ , and 10 mg of azocoll (Sigma), a covalently modified, insoluble form of the protein collagen which releases a soluble chromophore when proteolytically cleaved. The solutions were incubated at  $37^\circ\text{C}$  for 30 minutes with constant shaking. The reactions were then centrifuged to remove the insoluble azocoll and the  $A_{620}$  of the solution determined. Inhibitors were pre-incubated with the reaction mix for 5 minutes at  $37^\circ\text{C}$ . Where a very small amount of residual protease activity was to be measured,  $^{14}\text{C}$ -casein or resorufin-labelled casein was used as the substrate. In the  $^{14}\text{C}$ -casein test, culture supernatant (100  $\mu\text{l}$ ) was added to 100  $\mu\text{l}$  of 50 mM Tris, 5 mM  $\text{CaCl}_2$  containing  $1 \times 10^5$  cpm of  $^{14}\text{C}$ -casein (New England Nuclear). The solutions were incubated at  $37^\circ\text{C}$  for 30 minutes. The reactions were then placed on ice and 20  $\mu\text{g}$  of BSA were added as carrier protein. Cold 10% TCA (600  $\mu\text{l}$ ) was added and the mix was kept on ice for 10 minutes. The solutions were centrifuged to spin out the precipitated protein and the supernatants counted in a scintillation counter. The resorufin-labelled casein assay involved incubation of culture supernatant with an equal volume of resorufin labelled casein in Tris-Cl buffer, pH 8.0, at  $37^\circ\text{C}$  for various times. Following incubation, unhydrolyzed substrate was precipitated with TCA and the resulting chromogenic supernatant was quantitated spectrophotometrically.

#### Deletion of the npr gene

According to Yang et al. (J. Bact., 1984, 160: 15), the npr gene is contained within overlapping EcoRI and HindIII restriction fragments of B. subtilis DNA, and a majority of the gene sequence is located on the 2.4 kb HindIII fragment. This fragment was chosen for creation of the npr deletion.

An individual clone containing the 2.4 kb HindIII fragment was isolated from a clone bank of genomic HindIII fragments prepared as follows. Chromosomal DNA was isolated from B. subtilis strain IS75, digested with HindIII and size fractionated by electrophoresis on a 0.8% agarose gel. DNA in the 2-4 kb size range was electroeluted from the gel. The purified DNA was ligated to HindIII digested and alkaline phosphatase treated pUC9 DNA (an E. coli replicon commercially available from Bethesda Research Labs, Rockville, Md), transformed into competent cells of E. coli strain JM107, and plated on LB + 50  $\mu\text{g}/\text{ml}$  ampicillin resulting in 1000  $\text{Amp}^R$  colonies.

Colonies containing the cloned neutral protease gene fragment were identified by standard colony hybridization methods (Maniatis et al., 1983, "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor, New York). Briefly, transformants are transferred to nitrocellulose filters, lysed to release the nucleic acids and probed with an npr specific probe. A 20 base oligonucleotide complementary to the npr gene sequence between nucleotides 520 and 540 (Yang et al., *supra*) was used as the probe. The sequence is 5'GGCACGCTTGCTCAAGCAC 3'. A representative clone containing the 2.4 kb HindIII insert was identified and named p371 (Fig. 1).

A deleted form of the npr gene in p371 was derived *in vitro*. A 580 bp internal RsaI fragment was deleted by digesting p371 DNA with RsaI and HindIII. The 600 bp HindIII-RsaI fragment spanning the 5' end of the gene and the 1220 bp RsaI-HindIII fragment spanning the 3' end of the gene (see Fig. 1) were isolated and cloned into HindIII and alkaline phosphatase treated pUC9. This resulted in the deletion of the center portion of the npr gene. The ligated DNA was transformed into E. coli JM107. A clone having the desired deletion within the npr gene was identified by restriction enzyme analysis. This plasmid is designated p371A.

A gene encoding a selectable marker was included on the vector to facilitate the selection of integrants in *Bacillus*. The *Bacillus cat* gene, encoding resistance to chloramphenicol (Cm<sup>r</sup>), was isolated from plasmid pMI1101 (Youngman et al., 1984, Plasmid 12:1-9) on a 1.3 kb *Sall* fragment and cloned into the *Sall* site of p371Δ. This DNA was transformed into *E. coli* JM107 and transformants were screened for chloramphenicol resistance. A representative plasmid containing both the deleted *npr* gene and the *cat* gene was named p371ΔCm (Fig. 1).

The vector p371ΔCm was derived from the *E. coli* replicon pUC19 and is therefore unable to replicate in a *Bacillus* host. The wild-type *npr* gene in the chromosome of the recipient host was exchanged for the deleted *npr* gene contained on the vector by reciprocal recombination between homologous sequences. The Cm<sup>r</sup> marker gene enabled the selection of cells into which the vector, inclusive of the protease gene sequence, had integrated.

Vector sequences that integrated with the deleted *npr* gene were spontaneously resolved from the chromosome at a low frequency, taking a copy of the *npr* gene along with them. Retention of the deleted protease gene in the chromosome was then confirmed by assaying for the lack of protease activity in the Cm<sup>r</sup> segregants.

Specifically, competent *B. subtilis* IS75 cells were transformed with p371ΔCm and selected for Cm<sup>r</sup>. Approximately 2000 colonies, which had presumably integrated the deleted *npr* gene adjacent to, or in place of, the wild type gene, were selected which were resistant to chloramphenicol. Approximately 25% of the colonies formed smaller zones of clearing on starch agar indicating that the wild-type gene had been replaced with the deleted form of the gene. No neutral protease activity was detected in supernatants from these cell cultures. In contrast, high levels of neutral protease activity were assayed in culture fluids from wild type IS75 cells. Segregants which contained a single integrated copy of the deleted protease genes, but which had eliminated the vector sequences were then selected as follows.

A culture of Cm<sup>r</sup> colonies was grown overnight in liquid media without selection then plated onto TBAB media. These colonies were then replicated onto media containing chloramphenicol and those that did not grow in the presence of chloramphenicol were identified and selected from the original plate. One such Npr negative colony was selected and designated IS75NA.

Deletion within the *npr* gene in IS75NA was confirmed by standard Southern blot analysis (Southern, 1977, J. Mol. Biol. 98: 503) of *Hind*III digested DNA isolated from *B. subtilis* IS75NA and IS75NA probed with the <sup>32</sup>P-labelled *npr*-specific oligonucleotide. The probe hybridized with a 2.4 kb *Hind*III fragment in wild-type IS75N DNA and with a 1.8 kb fragment in IS75N Δ DNA indicating that 600 bp of the *npr* gene were deleted in IS75NA (see Fig. 2).

#### Deletion of the *apr* gene

To clone the subtilisin gene (*apr*) a genomic library from IS75 DNA was first prepared. Chromosomal DNA was isolated and digested with *Eco*RI and separated by electrophoresis through a 0.8% agarose gel. Fragments in the 5-8 kb size range were purified by electroelution from the gel. The fragments were ligated with *Eco*RI digested pBR328 DNA (publicly available from New England Biolabs) and transformed into competent *E. coli* JM107 cells. Transformants were screened for plasmids containing *apr* gene inserts by hybridizing with a synthetic <sup>32</sup>P-labelled 17-mer oligonucleotide probe which was complementary to the *apr* gene sequence between nucleotides 503 and 520 (Stahl et al., 1984, J. Bact. 158: 411). A clone with a 6.5 kb *Eco*RI insert that hybridized with the probe was selected and named pAS007 (Fig. 3). The 6.5 kb fragment contained the entire coding sequence of the subtilisin gene.

A mutant of the *apr* gene was created by deleting the two internal *Hpa*I fragments (Fig. 3). pAS007 was first digested with *Hpa*I and then recircularized by ligating in a dilute solution (5ug/ml) to eliminate the two *Hpa*I fragments. Approximately 200 Amp<sup>r</sup> colonies arose following transformation of JM107 cells. One of these transformants contained a 4.8 kb *Eco*RI insert with one internal *Hpa*I site. It was designated pAS12. The deletion in the *apr* gene extended 500 bp beyond the 3' end of the gene, however this DNA apparently did not contain any genes that were essential to *B. subtilis*.

A 1.3 kb *Sall* fragment containing the *Bacillus cat* gene was cloned into the *Sall* site of pAS12 (described above) for selection of integrants in the *Bacillus* host chromosome. The plasmid DNA was transformed into *E. coli* JM107, plated on media containing ampicillin and approximately 50 Amp<sup>r</sup> colonies were recovered and replica plated onto media containing 7.5 ug/ml chloramphenicol. Three of the 50 colonies were Cm<sup>r</sup>. Plasmid DNA was isolated from these three clones and analyzed by restriction digestion. One of the plasmids had the desired restriction pattern and was named pAS13 (Fig. 3).

To promote integration of the deleted protease gene into the *B. subtilis* chromosome, pAS13 was introduced into strain IS75NA and selected for Cm<sup>r</sup> transformants. The transformants were then screened for replacement of the wild-type *apr* gene with the deleted gene by plating on TBAB plates containing 5 ug/ml Cm and 1.5% casein. Several of the colonies which did not produce halos were selected for loss of the Cm<sup>r</sup> gene as described above. A representative transformant was chosen and designated GP199.

Protease activity was assayed in the culture fluids from the double protease deleted strain, as well as in the strain having only the deleted neutral protease gene. Protease activity in Npr<sup>-</sup>, Apr<sup>-</sup> mutant cells was approximately 4-7% of wild type levels whereas the Npr<sup>-</sup> mutant exhibited higher levels of protease activity.

amyE Mutation

Protease deficient strains were tested in connection with the production of a *Bacillus* amylase. To assay the levels of amylase produced by various plasmid constructs it was necessary to introduce a mutant amylase gene into the host in place of the wild type gene. This step is not essential to the present invention and does not affect the level of protease activity; it was performed only because plasmid encoded amylase levels could not be determined in the presence of the chromosomally encoded amylase. The *amyE* allele was transformed from *B. subtilis* strain JF206 (*trpC2*, *amyE*) into GP199 by a transformation/selection process known as congression. This process relies on the ability of competent *B. subtilis* cells to be transformed by more than one piece of chromosomal DNA when the transforming DNA is provided in excess. The process involves initial selection of competent cells in the population by assaying for expression of a selectable marker gene which subsequently facilitates screening for co transfer of an unselectable marker, such as inability to produce amylase.

Total chromosomal DNA was isolated from JF206 or a similar strain containing an *amyE* mutation. Saturating concentrations (~1 µg) were transformed into competent GP199 (*met*<sup>-</sup>, *leu*<sup>-</sup>, *his*<sup>-</sup>) and His<sup>+</sup> transformants were selected on minimal media supplemented with methionine and leucine. The transformants were screened for an amylase minus phenotype on plates having a layer of top agar containing starch-azure. Five percent of the His<sup>+</sup> colonies were unable to produce halos indicating that the amylase gene was defective. One such transformant was assayed for the protease-deficient phenotype and was designated GP200.

Supernatant samples from cultures of the double protease mutant were assayed for protease activity using azocoll as the substrate. When assayed on this substrate, protease activity in the double protease mutant strain was 4% of wild type levels. When the more sensitive substrate <sup>14</sup>C-casein was used in the protease assay, the double mutant displayed 5-7% of the wild type *B. subtilis* activity. Although protease activity in this strain was low, we discovered that certain heterologous gene products produced by these protease deficient cells were not stable, indicating the presence of residual protease activity. We then sought to identify and mutate the gene(s) responsible for the residual protease activity.

In order to characterize the residual protease activity, a number of known protease inhibitors were tested for their ability to reduce protease levels in cultures of the double protease mutant strain. PMSF (phenylmethylsulfonyl fluoride), a known inhibitor of serine protease activity, was found to be the most effective. The addition of PMSF to growing cultures of Apr<sup>-</sup> Npr<sup>-</sup> *Bacillus* cells successfully increased the stability of heterologous peptides and proteins synthesized in and secreted from these cells. These results indicated that at least a portion of the residual degradative activity was due to a serine protease.

Subtilisin is the major serine protease to be secreted by *B. subtilis*; however, the serine protease encoded by the *isp-1* gene (*ISP-1*) has been shown to accumulate intracellularly during sporulation (Srivastava et al., 1981, Arch. Microbiol., 129: 227). In order to find out if the residual protease activity was due to *isp-1*, a deleted version of the *isp-1* gene was created *in vitro* and incorporated into the double-protease deleted strain.

Deletion of the *isp-1* gene

The *isp-1* gene is contained within a 2.7 kb *Bam*HI fragment of *B. subtilis* chromosomal DNA (Koide et al., 1986, J. Bact., 167:110). Purified DNA was digested with *Bam*HI and fragments in the 2.7 kb size range were electroeluted from an agarose gel, ligated into *Bam*HI digested pBR328 and transformed into *E. coli* JM107 cells. One Amp<sup>r</sup> colony that produced a halo on LB media containing 1% casein was selected and named pISP-1. Restriction analysis of the DNA indicated that pISP-1 carried a 2.7 kb *Bam*HI insert which hybridized with a synthetic 25 base <sup>32</sup>P-labeled oligonucleotide probe [5'-ATGAATGGTGAAATCCGCTTGATCC 3'] complementary to the *isp-1* gene sequence (Koide et al, *supra*). The restriction pattern generated by *Sal*I and *Eco*RI digestions confirmed the presence of the *isp-1* gene in pISP-1.

A deletion was created within the *isp-1* gene by taking advantage of a unique *Sal*I site located in the center of the gene. Because there was an additional *Sal*I site in the vector, the 2.7 kb *Bam*HI gene insert was first cloned into the *Bam*HI site of a derivative of pBR322 (pAL4) from which the *Sal*I site had been eliminated (Fig. 4). The resulting plasmid, pAL5, therefore had a unique *Sal*I site within the *isp-1* gene. pAL5 DNA was digested with *Sal*I, treated with *Bal*31 exonuclease for five minutes at 37°C to delete a portion of the gene sequence, and religated. The DNA was transformed into JM107 and resulting Amp<sup>r</sup> colonies were screened for a *Bam*HI insert of reduced size. A plasmid with a 1.2 kb deletion within the *Bam*HI insert was selected and named pAL6 (Fig. 4).

The *cat* gene was purified from the *E. coli* plasmid pMI1101 on a *Sal*I fragment as above and cloned into pAL6 at the *Eco*RV site. The resulting DNA was transformed into the double protease mutant strain (GP200) and integrants containing the deleted *ISP-1* gene were selected as described above. The triple-protease deleted strain is called GP208 (*aprA*, *nprA*, *isp-1Δ*). Using a casein substrate, protease activity was measured in the triple-mutant strain (Apr<sup>-</sup>, Npr<sup>-</sup>, *isp-1*<sup>-</sup>) and found to be 4% of the wild type level, about the same as the double mutant strain.

The remaining 4% residual protease activity was apparently due either to a previously described esterase called bacilloprotease F (Roitsch et al., 1983, J. Bact., 155: 145), or to a previously unknown and unidentified protease gene(s).

#### Introduction of a sporulation mutation

Because it had been shown that the production of certain proteases was associated with the process of sporulation in *B. subtilis*, we reasoned that it may be useful to include a mutation which blocked sporulation in our protease deficient hosts and thus further reduce sporulation-dependent protease production in these strains. Mutations that block the sporulation process at stage 0 reduce the level of protease produced, but do not eliminate the ability of the cells to be transformed by purified DNA. *spoOA* mutations have been shown to be particularly efficient at decreasing protease synthesis (Ferrari et al., 1986, J. Bact. 166:173).

We first introduced the *spoOA* mutation into the double protease deficient strain as one aspect of our strategy to eliminate the production of the serine protease, *isp-1*. We ultimately introduced the *spoOA* mutation into the triple- and quadruple- protease deficient strains. This feature is useful only when a promoter, contained within an expression vector for the production of heterologous gene products in a *Bacillus* host, is not a sporulation-specific promoter (e.g. the *spoVG* promoter).

Saturating amounts of chromosomal DNA were prepared from *B. subtilis* strain JH646 (*spoOA*, *Prot*<sup>+</sup>, *Amy*<sup>+</sup>, *Met*<sup>+</sup>) or similar strains having a *spoOA* mutation, and transformed into competent GP200 cells (*Spot*<sup>+</sup>, *Prot*<sup>-</sup>, *Amy*<sup>-</sup>, *Met*<sup>-</sup>). *Met*<sup>+</sup> transformants were selected by growth on minimal media plates. Resulting transformants were then screened for co-transformation of the *spoOA* allele by assaying on sporulation medium (Difco) for the sporulation deficiency phenotype, characterised by smooth colony morphology and the lack of production of a brown pigment. Approximately 9% of the *Met*<sup>+</sup> transformants appeared to be co-transformed with the *spoOA* allele; a number of these were rescreened on plates containing either starch-azure or casein to confirm that the recipients had not also been co-transformed with intact amylase or protease genes from the donor DNA. One transformant that did not exhibit detectable protease activity was designated GP205 (*spoOA*, *amyE*<sup>-</sup>, *aprA*<sup>-</sup>, *nprE*<sup>-</sup>). Protease levels produced by this host were 0.1% of the level found in the extracellular fluid of the *Spot*<sup>+</sup> host, when casein was the substrate.

In the same manner, the *spoOA* mutation was introduced into the triple protease deficient mutant GP208 (*aprA*<sup>-</sup>, *nprA*<sup>-</sup>, *isp-1A*) and the quadruple protease deficient mutant GP216 (*aprA*<sup>-</sup>, *nprA*<sup>-</sup>, *isp-1A*, *eprA*<sup>-</sup> and described below). The resulting *Spot*<sup>-</sup> strains are GP210 and GP235, respectively. These strains are useful when the expression vector is not based on a sporulation dependent promoter.

#### Identification of a new protease gene

We expected that the isolation and cloning of the gene(s) responsible for the remaining protease activity would be difficult using conventional methods because cells did not produce large enough amounts of the enzyme(s) to detect by the appearance of halos on casein plates. We reasoned that it should be possible to isolate the gene(s) if it were replicated on a high-copy vector so that the copy number of the gene(s), and thus protease production, would be amplified to detectable levels. This strategy enabled us to isolate a novel protease gene from a *Bacillus* gene bank. The first of these new protease genes has been named *epr* (extracellular protease). Deletion mutants of this new gene were derived *in vitro* and introduced into the *Apr*<sup>-</sup> *Npr*<sup>-</sup> *Ispr*<sup>-</sup> *Bacillus* host strains by gene replacement methods as described above.

#### Cloning the *epr* gene

In order to obtain a clone carrying a gene responsible for residual protease activity, a *Sau*3A library of *B. subtilis* GP208 DNA was prepared. Chromosomal DNA was isolated, subjected to partial digestion with *Sau*3A and size-fractionated on an agarose gel. Fragments in the 3-7 kb size range were eluted from the gel and cloned into the *Bgl*II site of pEc224, a shuttle vector capable of replicating in both *E. coli* and *Bacillus* (derived by ligating the large *Eco*RI-*Pvu*II fragment of pBR322 with the large *Eco*RI-*Pvu*II fragment of pBD64 (Gryczan et al., 1978, PNAS 75:1428)). The ligated DNA was transformed into *E. coli* JM107 and plated on media containing casein. None of the 1200 *E. coli* colonies produced halos on casein plates, however by restriction analysis of the purified plasmid DNA, approximately 90% of the clones contained inserts with an average size of about 4 kb. The clones were transformed into a *Bacillus* host to screen for protease activity as follows. *E. coli* transformants were pooled in twelve groups of 100 colonies each (G1-G12). The pooled colonies were grown in liquid media (LB + 50 ug/ml ampicillin), plasmid DNA was isolated, transformed into *B. subtilis* GP208 (*aprA*<sup>-</sup>, *nprA*<sup>-</sup>, *isp-1A*) and plated on casein plates. Halos were observed around approximately 5% of transformants from pool G11. Plasmid DNA was isolated from each of the positive colonies and mapped by restriction enzyme digestion. All of the transformants contained an identical insert of approximately 4 kb (Fig. 5). One of these plasmids was selected and named pNP1.

Characterization of epr protease activity

The residual protease activity remaining in GP208 (*aprA*, *nprA*, *isp-1Δ*) cultures accounted for only a small percentage of the total protease activity produced by the host. In order to characterize the type of protease encoded by the *epr* gene, the effect of different inhibitors on the protease secreted by *B. subtilis* GP208/pNP1 was examined.

Culture media was obtained two hours into stationary phase and assayed using <sup>14</sup>C-casein as the substrate. The level of protease activity present in GP208 was not high enough to detect in the standard protease assay described above, however, appreciable protease activity was detected in the culture medium of GP208/pNP1, carrying the amplified *epr* gene. The *epr* protease activity was inhibited in the presence of both 10 mM EDTA and 1mM PMSF suggesting that it encodes a serine protease which requires the presence of a cation for activity. (*isp-1*, another serine protease, is also inhibited by EDTA and PMSF.)

Subcloning the epr gene

A 2.7 kb *HpaI-SalI* subfragment was isolated from the pNP1 insert and cloned into pBs81/6, a derivative of pBD64 (derived by changing the *PvuII* site to a *HindIII* site using synthetic linkers). Transformants carrying this subcloned fragment were capable of producing halos on casein plates, indicating that the entire protease gene was present within this fragment. A representative clone was named pNP3.

The location of the gene within the pNP3 insert was further defined by subcloning a 1.6 kb *EcoRV* subfragment into pBs81/6 and selecting for the colonies producing halos on casein plates. A clone which produced a halo, and which also contained the 1.6 kb insert shown in Fig. 5, was designated pNP5. The presence of the protease gene within this fragment was confirmed by deleting this portion of the 4 kb insert from pNP1. pNP1 was digested with *EcoRV* and religated under conditions which favored recircularization of the vector without incorporation of the 1.6 kb *EcoRV* insert. The DNA was transformed into GP208 and colonies were screened on casein plates. Greater than 95% of the transformants did not produce halos, indicating that the protease gene had been deleted from these clones. A representative clone was selected and is designated pNP6. (The small percentage of colonies that produced halos were presumed to have vectors carrying the native *epr* gene resulting from recombination between the chromosomal copy of the gene and homologous sequences within the plasmid.)

Nucleotide and deduced amino acid sequence of the epr gene

Subcloning and deletion experiments established that most of the protease gene was contained on the 1.6 kb *EcoRV* fragment (Fig. 5). Determination of the nucleotide sequence of the 1.6 kb *EcoRV* fragment (Fig. 6) revealed an open reading frame which covered almost the entire fragment starting 450 bp from the left end and proceeding through the right end (see Fig. 2). Comparison of the deduced amino acid sequence with other amino acid sequences in GENBANK indicated that the protein encoded by the ORF had strong homology (approximately 40%) to both subtilisin (Stahl et al., 1984, *J. Bact.*, **158**:411) and *isp-1* (Koide et al., 1986, *J. Bact.*, **167**:110) from *B. subtilis* 168. The most probable initiation codon for this protease gene is the ATG at position 1 in Figure 6. This ATG (second codon in the ORF) is preceded by an excellent consensus *B. subtilis* ribosome binding site (AAAGGAGATGA). In addition, the first 26 amino acids following this methionine resemble a typical *B. subtilis* signal sequence: a short sequence containing two positively-charged amino acids, followed by 15 hydrophobic amino acids, a helix-breaking proline, and a typical Ala X Ala signal peptidase cleavage site (Perlman et al., 1983, *J. Mol. Biol.*, **167**:391).

Sequence analysis indicated that the ORF continued past the end of the downstream *EcoRV* site, even though the 1.6 kb *EcoRV* fragment was sufficient to encode *Epr* protease activity. To map the 3' end of the gene, the DNA sequence of the overlapping *KpnI* to *SalI* fragment was determined (Fig. 6). As shown in Figure 2, the end of the ORF was found 717 bp downstream of the *EcoRV* site and the entire *epr* gene was found to encode a 645 amino acid protein, the first approximately 380 amino acids of which are homologous to subtilisin (Fig. 6). The C-terminal approximately 240 amino acids are apparently not essential for proteolytic activity since N-terminal 405 amino acids encoded in the 1.6 kb *EcoRV* fragment are sufficient for protease activity.

Structure of the epr protein

*In vitro* transcription-translation experiments were used to confirm the size of the protein. Plasmid pNP3 DNA (containing the 2.7 kb *HpaI-SalI* fragment with the entire *epr* gene) was added to an S30-coupled transcription/translation system (New England Nuclear) resulting in the synthesis of a protein of approximately 75,000 daltons. (Additional proteins of 60,000 and 34,000 daltons were also observed and presumably represented processed or degraded forms of the 75,000 dalton protein.) This size agreed reasonably well with the predicted molecular weight of 69,702 daltons for the primary product based on the deduced amino acid sequence.



The homology between the amino-terminal half of the *epr* protease and subtilisin suggests that Epr might also be produced as a preproenzyme with a pro sequence of similar size to that of subtilisin (70-80 amino acids). If true, and if there were no additional processing, this would argue that the mature Epr enzyme has a molecular weight of around 58,000. Examination of culture supernatants, however, indicated that the protein has a molecular weight of about 34,000. Comparison by SDS-PAGE of the proteins secreted by *B. subtilis* strain GP208 containing a plasmid with the *epr* gene (pNP3 or pNP5) or just the parent plasmid alone (pBs81/6) showed that the 2.7 kb *HpaI-SalI* fragment (Figure 1) cloned in pNP3 directed the production of proteins of about 34,000 and 38,000 daltons, whereas the 1.6 kb *EcoRV* fragment cloned in pNP5 in the same orientation (Fig. 1) directed production of just the 34,000 dalton protein. The two proteins appear to be different forms of the Epr protease, resulting from either processing or proteolytic degradation. Clearly, the 1.6 kb *EcoRV* fragment, which lacks the 3' third of the *epr* gene, is capable of directing the production of an active protease similar in size to that observed when the entire gene is present. This suggests that the protease normally undergoes C-terminal processing.

*Bacillus* strain GP208 containing the *epr* gene on plasmid pNP3 can be used to overproduce the Epr protease, which can then be purified by conventional procedures.

#### Location of *epr* on the *B. subtilis* chromosome

To map *epr* on the *B. subtilis* chromosome, we introduced a drug-resistance marker into the chromosome at the site of the *epr* gene, and used phage PBS1-mediated transduction to determine the location of the insertion. A 1.3 kb *EcoRI* fragment containing a chloramphenicol acetyltransferase (*cat*) gene was cloned into the unique *EcoRI* site on an *E. coli* plasmid containing the *epr* gene (pNP2 is depicted in Figure 7). The resulting plasmid (pNP7) was used to transform *B. subtilis* GP208, and chloramphenicol resistant transformants were selected. Since the plasmid cannot replicate autonomously in *B. subtilis*, the *Cm<sup>r</sup>* transformants were expected to arise by virtue of a single, reciprocal recombination event between the cloned *epr* gene on the plasmid and the chromosomal copy of the gene. Southern hybridization confirmed that the *cat* gene had integrated into the chromosome at the site of the cloned *epr* gene. Mapping experiments indicated that the inserted *cat* gene and *epr* gene are tightly linked to *sacA321* (77% co-transduction), are weakly linked to *purA16* (5% co-transduction), and unlinked to *hisA1*. These findings suggest that the *epr* gene is located near *sacA* in an area of the genetic map which does not contain any other known protease genes.

#### Construction of *epr* Deletion Mutant

To create a mutant *Bacillus* devoid of protease activity a deletion in the 5' end of the cloned gene was constructed and then used to replace the wild type gene in the chromosome. pNP2 was first digested with *Bam*HI, which cleaves at a unique site within the *epr* gene, then the linear plasmid DNA was treated with *Bal*31 exonuclease for 5 minutes at 32°C, religated and transformed into *E. coli* JM107. Plasmid DNA was isolated from 20 transformants, digested with *EcoRI* and *Hind*III to remove the *epr* gene insert and analyzed by gel electrophoresis. One of the plasmids had a 2.3 kb *EcoRI-Hind*III fragment replacing the 2.7 kb fragment indicating that approximately 400 base pairs had been deleted from the *epr* gene sequence. This plasmid was designated pNP8 (Fig. 7). This deletion mutant was introduced into *B. subtilis* GP208 by gene replacement methods as described above. The *cat* gene, contained on an *EcoRI* fragment from pEccl, was introduced into the *EcoRI* site on pNP8 to create pNP9 (Fig. 7). This *E. coli* plasmid was used to transform *B. subtilis* GP208 and *Cm<sup>r</sup>* colonies were selected. Most of the transformants produced a very small halo and the remaining 30% produced no halos on casein plates. The absence of a halo and therefore protease activity resulted from a double crossover between chromosomal DNA and homologous sequences from a concatamer of the plasmid DNA; these strains contain the *E. coli* replicon and *cat* gene flanked by two copies of the deleted *epr* gene. To screen for a strain that had undergone a recombination event between the two copies of the *epr* gene to resolve the duplication, but which had jettisoned the *cat* gene and the *E. coli* replicon, a single colony was selected and grown overnight in rich medium without drug selection. Individual colonies arising from this culture were then screened for drug resistance and about 0.1% of these were found to be *Cm<sup>r</sup>*. One such strain, GP216, containing deletions within the four protease genes (*apr*, *npr*, *isp-1* and *epr*) was selected for further study.

The deletion in the chromosomal *epr* gene was confirmed by Southern hybridization. GP216, like the *Cm<sup>r</sup>* parent strain, failed to produce a halo on casein plates. In liquid cultures, however, <sup>14</sup>C-casein protease assays indicated that the *epr* mutation alone does not entirely eliminate residual protease activity. A strain with deletions in *epr*, *apr*, *npr*, and *isp*, did not produce significantly less protease than a strain with mutations in just *apr*, *npr*, and *isp*. Finally, growth and sporulation of the quadruple protease deleted strain were assayed using standard laboratory media. No differences were observed in growth in LB medium when compared to the wild-type strain. Similarly, no appreciable differences were seen in sporulation frequency after growth on DSM medium for 30 hours (1 X 10<sup>8</sup> spores/ml for both GP208 and GP216).

Identification of Novel Proteolytic Activities

Strain of *B. subtilis* have been deleted for four non-essential protease genes, *apr*, *npr*, *isp-1* and *epi*. These deletions reduce total extracellular protease levels in culture supernatants of Spo<sup>+</sup> hosts by about 96% compared to the wild-type strain, but it is desirable to decrease or eliminate the remaining 4% residual protease activity for the production of protease-labile products in *Bacillus*.

Using the azocoll assay, we have identified two novel proteases that account for this residual activity in GP227, a multiple protease-deficient *B. subtilis* strain (*aprA*, *nprA*, *prA*, *isp-1Δ*) which also contains a gene, *sacQ*<sup>\*</sup>, encoding a regulatory protein. The *sacQ*<sup>\*</sup> gene product functions by enhancing the production of degradative enzymes in *Bacillus*, including the residual protease activity(s) as described in our European Patent Application 86308356.4 (Publication No. EP-A-0227260) the disclosure of which is to be regarded as hereby incorporated by reference. Due to enhancement by *sacQ*<sup>\*</sup>, strain GP227 produces substantially more protease activity than GP216, which lacks *sacQ*<sup>\*</sup>.

In general, supernatants from cultures of *B. subtilis* GP227 were concentrated, fractionated by passage over a gel filtration column and assayed for protease activity. Two separate peaks of activity were eluted from the column and designated RP-I and RP-II (residual protease) for the larger and smaller molecular weight species, respectively. Subsequent analysis of these two peaks confirmed that each accounted for a distinct enzymatic activity. The isolation and characterization of the RP-I and RP-II proteins, and the creation of a deletion mutation in each of the RP-I and RP-II genes are described below.

Isolation and Characterization of RP-I

A simple and efficient purification scheme was developed for the isolation of RP-I from spent culture fluids. Cultures were grown in modified MRS lactobacillus media (Difco, with maltose substituted for glucose) and concentrated approximately 10-fold using an Amicon CH2PR system equipped with a S1Y10 spiral cartridge. The concentrated supernatant was dialyzed in place against 50mM MES, 0.4M NaCl, pH 6.8, and fractionated over a SW3000 HPLC gel filtration column equilibrated with the same buffer. The fractions containing protease activity were identified using a modification of the azocoll assay described above.

Fractions which were positive for the protease activity, corresponding to the higher molecular weight species, were pooled and concentrated using a stirred cell equipped with a YM5 membrane, dialyzed vs. 50mM MES, 100mM KCl, pH 6.7 and applied to a benzamidine-Sepharose liquid affinity column equilibrated with the same buffer. Most of the protein applied to the column (97%) failed to bind to the resin, however RP-I protein bound quantitatively and was eluted from the column with 250mM KCl.

SDS-PAGE analysis of the benzamidine purified RP-I revealed that the protein was greater than 95% homogeneous, and had a molecular weight of approximately 47,000 daltons. Purification by the above outlined procedure resulted in a 140-fold increase in specific activity, and an overall recovery of about 10%.

Isoelectric focusing gels revealed that RP-I has a pI between 4.4 and 4.7, indicating a high acidic/basic residue composition. The enzyme has a pH optimum of 8.0 and a temperature maximum of 60° C when azocoll is used as the substrate. It is completely inhibited by PMSF, indicating that it is a serine protease, but it is not inhibited by EDTA, even at concentrations as high as 50mM.

RP-I catalyzes the hydrolysis of protein substrates such as denatured collagen and casing as well as ester substrates (O=C-O- vs. O=C-N- linkages) such as N- $\alpha$ -benzoyl-L-arginine ethyl ester, phenylalanine methyl ester, tyrosine ethyl ester and phenylalanine ethyl ester, but does not catalyze hydrolysis of the arginine peptide bond in the synthetic substrate N- $\alpha$ -benzoyl-L-arginine-4-nitrilide. Collectively, these data demonstrate that RP-I is a serine endoprotease that has esterase activity and belongs to the subtilisin superfamily of serine proteases. Furthermore, these characteristics indicate that RP-I may be the enzyme commonly referred to as Bacillopeptidase F (Boyer et al., 1968, Arch Biochem, Biophys., 128:442 and Roitsch et al., 1983, J. Bact., 155:145). Although Bacillopeptidase F has been reported to be a glycoprotein, we have not found carbohydrate to be associated with RP-I.

Cloning the Gene for RP-I

The sequence of the amino-terminal 28 amino acids of RP-I was determined by sequential Edman degradation on an automatic gas phase sequencer and is depicted in Figure 8. A DNA probe sequence (81 nucleotides) was synthesized based on the most frequent codon usage for these amino acids in *B. subtilis* (Figure 8). The N-terminal amino acid sequence of RP-I contains two tryptophan residues (positions 7 and 18). Since tryptophan has no codon degeneracy, this facilitated the construction of a probe that was highly specific for the gene encoding RP-I.

High molecular weight DNA was isolated from *B. subtilis* strain GP216, digested with each of several different restriction endonucleases and fragments were separated by electrophoresis through a 0.8% agarose gel. The gel was blotted onto a nitrocellulose filter by the method of Southern (*supra*) and hybridized overnight with the <sup>32</sup>P end-labeled

synthetic RP-I specific probe under a mi-stringent condition (5X SSC, 20% formamide, 1X Denhardt's at 37° C). Following hybridization, the blot was washed for one hour at room temperature in 2X SSC, 0.1% SDS.

The RP-I specific probe hybridized to only one band in each of the restriction digests indicating that the probe was specific for the RP-I gene. In the PstI digest, the probe hybridized to a 6.5 kb fragment which was a convenient size for cloning and was also large enough to contain most or all of the RP-I gene.

A clone bank containing PstII inserts in the 6-7 kb size range was prepared from B. subtilis DNA as follows. Chromosomal DNA of strain GP216 was digested with PstII and separated on a 0.8% agarose gel. DNA fragments of 6-7 kb were purified from the gel by electrophoresis and ligated with PstII digested pBR322 that had been treated with calf intestinal phosphatase to prevent recircularization of the vector upon treatment with ligase. The ligated DNA was transformed into competent E. coli DH5 cells and plated on media containing tetracycline. Approximately  $3 \times 10^4$  Tet<sup>r</sup> transformants resulted, 80% of which contained plasmids with inserts in the 6-7 kb size range.

A set of 550 transformants was screened for the presence of the RP-I insert by colony hybridization with the <sup>32</sup>P-labeled RP-I specific probe and seven of these transformants were found to hybridize strongly with the probe. Plasmid DNA was isolated from six of the positive clones and the restriction digest patterns were analyzed with PstII and HindIII.

All six clones had identical restriction patterns, and the plasmid from one of them was designated pCR83. Using a variety of restriction enzymes, the restriction map of pCR83 insert shown in Figure 9 was derived. The RP-I oligomer probe, which encodes the N-terminal 28 amino acids of the mature RP-I protease, was hybridized with restriction digests of pCR83 by the method of Southern (supra). The probe was found to hybridize with a 0.65 kb ClaI-EcoRV fragment suggesting that this fragment contained the 5' end of the gene. In order to determine the orientation of the RP-I gene, the strands of the ClaI-EcoRV fragment were separately cloned into the single-stranded phage M13. The M13 clones were then probed with the RP-I oligomer and the results indicated that the RP-I gene is oriented in the leftward to rightward direction according to the map in Figure 9.

The DNA sequence of a portion of the PstII insert, as shown in Figure 9, was determined, and an 81 base pair sequence (underlined in Figure 10) was found that corresponded exactly with the sequence encoding the first 28 amino acids of the protein. The BglII and ClaI sites designated in Fig. 10 are identical to those designated in Fig. 9 and, in addition, the EcoRV site is identical to that designated in the restriction enzyme map shown in Fig. 9. Portions of the untranslated region surrounding the RP-I coding region are also shown in Fig. 10; the DNA sequence underlined within the 5' untranslated region corresponds to the putative ribosome binding site.

The DNA sequence revealed an open reading frame that began at position -15 (in Figure 10) and proceeded through to position 2270. The most probable initiation codon for this open reading frame is the ATG at position 1 in Figure 10. This ATG is preceded by a ribosome binding site (AAAGGGGGATGA), which had a calculated  $\Delta G$  of -17.4 kcal. The first 29 amino acids following this Met resemble a B. subtilis signal sequence, with a short sequence containing five positively-charged amino acids, followed by 16 hydrophobic residues, a helix-breaking proline, and a typical Ala-X-Ala signal peptidase cleavage site. After the likely signal peptidase cleavage site, a "pro" region of 164 residues is followed by the beginning of the mature protein as confirmed by the determined N-terminal amino acid sequence. The first amino acid of the N-terminus, which was uncertain from the protein sequence, was confirmed as the Ala residue at position 583-585 from the DNA sequence. The entire mature protein was deduced to contain 496 amino acids with a predicted molecular weight of 52,729 daltons. This size was in reasonable agreement with the determined molecular weight of the purified protein of 47,000 daltons. In addition, the predicted isoelectric point of the mature enzyme (4.04) was in good agreement with the observed pI of 4.4-4.7. GENBANK revealed that the RP-I gene is partially homologous (30%) to subtilisin, to ISP-1 and, to a lesser extent (27%), to the apr gene product.

#### Cloning the RP-I gene on a multicopy replicon

The PstII fragment was removed from pCR83 and ligated into PstII linearized pBD9, a multicopy Bacillus replicon encoding erythromycin and kanamycin resistances. The ligated DNA was transformed into competent GP227 cells (the sacQ<sup>+</sup> enhancement strain) and kanamycin resistant transformants were selected. A plasmid carrying the 6.5 kb PstII insert was chosen and designated pCR88.

To confirm that this insert encoded the RP-I gene, GP227 cells containing pCR88 or pBD9 were grown in MRS medium under selective conditions for 50 hours at 37° C. Supernatant samples were collected and assayed for protease activity. Supernatants from the pCR88 cultures contained approximately 10-fold more protease activity than those from the pBD9 cultures. Furthermore, this secreted protease activity was inhibited by PMSF and, when fractionated on a denaturing protein gel, the supernatant from the pCR88 sample contained an extra protein of 47 kd. These results confirmed that the RP-I gene was encoded within the 6.5 kb fragment, and that cloning the sequence in a multicopy replicon leads to the overproduction of the RP-I protein.

Location of the RP-I Gene on the *B. Subtilis* Chromosome

We mapped the location of the RP-I gene (*bpr*) on the *B. subtilis* chromosome by integrating a drug resistance marker into the chromosome at the site of *bpr* and using phage PBS1-mediated transduction to determine the location of the *cat* insertion. A 1.3 kb *Sma*I fragment containing a chloramphenicol acetyltransferase (*cat*) gene was cloned into the unique *EcoRV* site of pCR92 (the 3.0 kb *Bgl*II of pCR83 cloned into pUC18). The *EcoRV* site is in the coding region of *bpr* (Figure 10). The resulting plasmid, pAS112, was linearized by digestion with *EcoR*I and then used to transform *B. subtilis* strain GP216, and chloramphenicol-resistant transformants were selected (GP238). *Cm<sup>r</sup>* transformants were expected to be the result of a double cross-over between the linear plasmid and the chromosome (marker replacement). Southern hybridization was used to confirm that the *cat* gene had integrated in the chromosome, interrupting the *bpr* gene. Mapping experiments indicating that the inserted *cat* gene and *bpr* were strongly linked to *pyr*D1 (89%) and weakly linked to *met*C (4%). The gene encoding the neutral protease gene (*npr*) also maps in this region of the chromosome, although *npr* is less tightly linked to *pyr* (45% and 32%) and more tightly linked to *met*C (18% and 21%) than is *bpr*.

Construction of a deleted version of the RP-I gene

An internal deletion in the RP-I sequence was generated *in vitro*. Deletion of the 650 bp sequence between the *Cla*I and *EcoRV* sites in the pCR83 insert removed the sequence encoding virtually the entire amino-terminal half of the mature RP-I protein. The deletion was made by the following procedure.

The 4.5 kb *Pst*I-*EcoR*I fragment of PCR78 (a pBR322 clone containing the 6.5 kb *Pst*I fragment) was isolated and ligated to pUC18 (a vector containing the *E. coli lacZ* gene encoding  $\beta$ -galactosidase) that had been digested with *EcoR*I and *Pst*I. The ligation mix was then transformed into *E. coli* DH5 cells. When plated onto LB media containing Xgal and ampicillin, eight white colonies resulted, indicating insertion of the fragment within the gene encoding  $\beta$ -galactosidase. Plasmid DNA prepared from these colonies indicated that seven of the eight colonies contained plasmids with the 4.5 kb insert. One such plasmid, pKT2, was digested with *EcoRV* and *Cla*I, treated with Klenow fragment to blunt the *Cla*I end and then recircularized by self-ligation. The ligated DNA was then transformed into *E. coli* DH5 cells. Approximately 100 transformants resulted and plasmid DNA was isolated from *Amp<sup>r</sup>* transformants and analyzed by restriction digestion. Eight of eight clones had the *Cla*I-*EcoRV* fragment deleted. One such plasmid was designated pKT2'. The *cat* gene, carried on an *EcoR*I fragment from pEccI was then ligated into pKT2' for use in selecting *Bacillus* integrants as described above. To insert the *cat* gene, pKT2' was digested with *EcoR*I, treated with calf intestine alkaline phosphatase and ligated to a 1.3 kb *EcoR*I fragment containing the *cat* gene. The ligated DNA was transformed into DH5 cells and the *Amp<sup>r</sup>* colonies that resulted were patched onto LB media containing chloramphenicol. Two of 100 colonies were *Cm<sup>r</sup>*. Plasmid DNA was isolated from these two clones and the presence of the 1.3 kb *cat* gene fragment was confirmed by restriction enzyme analysis of plasmid DNA. One of these plasmids, pKT3, was used to introduce the deleted gene into strain GP216 by gene replacement methods.

The DNA was transformed into GP216 and chloramphenicol resistant colonies were selected. Chromosomal DNA was extracted from 8 *Cm<sup>r</sup>* colonies and analyzed by Southern hybridization. One clone contained two copies of the deleted RP-I gene resulting from a double crossover between homologous sequences on the vector and in the chromosome. The clone was grown in the absence of chloramphenicol selection and was then replica plated onto TBAB media containing chloramphenicol. One *Cm<sup>r</sup>* colony was isolated and Southern analysis confirmed that the deleted gene had replaced the wild-type RP-I gene in the chromosome. This strain was designated GP240. Analysis of supernatants from cultures of GP240 confirmed the absence of RP-I activity.

Isolation and Characterization of RP-II

The purification scheme for RP-II was more extensive than for RP-I because RP-II failed to bind benzamidine-Sepharose or other protease-affinity resins, e.g., arginine-Sepharose and hemoglobin-agarose, and we thus found it necessary to use more conventional purification techniques such as ion exchange chromatography, gel filtration and polyacrylamide gel electrophoresis.

Concentrated crude supernatants of GP227 cultures were fractionated over DEAE-Sepharose (anion exchange) equilibrated at pH 6.8. At this pH the RP-II protein failed to bind the resin; however, approximately 80% of the total applied protein, including RP-I, bound the resin and was thus removed from the sample. The column eluate was then fractionated by cation exchange chromatography using CM-Sepharose CL-6B equilibrated at pH 6.8. RP-II was capable of binding to the resin under these conditions and was then eluted from the column with 0.5 M KCl. To further enhance the resolution of the cation exchange step, the RP-II eluate was then refractionated over a 4.6 x 250 mm WCX (weak cation exchange) HPLC column developed with a linear gradient of NaCl. The WCX pool was then size-fractionated over a TSK-125 HPLC column. The RP-II peak was then fractionated a second time over the same column yielding a

nearly homogeneous preparation of RP-II when analyzed by SDS-PAGE. The protease was purified over 6900-fold and represented approximately 0.01% of the total protein in culture fluids of GP227. Alternatively, approximately 30 fold more RP-II can be purified from a *Bacillus* strain that is RP-I<sup>+</sup> and contains the sacQ<sup>+</sup>-enhancing sequence (U.S. S.N. 921,343, assigned to the same assignee and hereby incorporated by reference), since the quantity of RP-II produced by such a strain is substantially increased, representing about 0.3% of total protein in the culture fluid.

RP-II was insensitive to PMSF treatment, and therefore is not a serine protease. SDS-PAGE analysis indicated that RP-II has a molecular mass of 27.3 kd. The failure of RP-II to bind DEAE at pH 6.7 and PAE-300 (an HPLC anionic column) at pH 8.3 indicated that the protein has a basic isoelectric point which is greater than 8.3 (pI = 8.7 by chromatofocusing). RP-II is highly sensitive to dithiothreitol (DTT, a sulfhydryl reducing agent), being quantitatively inhibited at levels as low as 1 mM in the azocoll assay. RP-II is also sensitive to combinations of other sulfhydryl reagents with metal chelators (i.e., mercaptoethanol with EDTA). Inhibition of proteases by sulfhydryl reagents is relatively rare and has only been described for a few proteases, such as collagenase from *C. histolyticum* and carboxypeptidase A. RP-II also possesses esterase activity as demonstrated by its ability to hydrolyze phenylalanine methyl ester and *n*-t-BOC-L-glutamic acid- $\alpha$ -phenyl ester.

In order to obtain the cleanest possible sample of RP-II for sequence analysis, a final purification step was used which involved separation by polyacrylamide gel electrophoresis. Following electrophoresis, proteins were transferred electrophoretically from the gel to a sheet of polyvinylidene difluoride (PVDF) membrane. RP-II was visualized on the hydrophobic membrane as a "wet-spot" and the corresponding area was cut from the sheet and its amino-terminal amino acid sequence determined.

The sequence of the 15 amino acid terminal residues of RP-II (Ser-Ile-Ile-Gly-Thr-Asp-Glu-Arg-Thr-Arg-Ile-Ser-Ser-Thr-Thr-) is rich in serine and arginine residues. Since both serine and arginine have a high degree of codon degeneracy, this increased the difficulty in creating a highly specific probe. Therefore, additional amino acid sequence information was obtained from internal peptides that contained one or more non-degenerate amino acid residues.

#### Sequence Analysis of Internal Peptide Fragments of RP-II

Tryptic peptides from purified RP-II were produced and isolated using reverse-phase HPLC. Since each of the amino acids tryptophan and methionine is encoded by only one amino acid codon, a synthetic nucleotide probe, or "guess-mer" that encodes one or more of either of these amino acids will be highly specific for its complementary nucleotide sequences.

An HPLC chromatogram of the RP-II trypsin digested mixture was monitored at three wavelengths: 210 nm (peptide bonds), 227 nm (aromatic residues, i.e., phenylalanine, tyrosine, tryptophan), and 292 nm (conjugated ring structure of tryptophan). The 292 nm trace was used to identify peptides of RP-II that contain a tryptophan residue. The 210 nm trace was used to obtain baseline resolved (i.e., single-species peptides) fragments for sequence analysis. Based on the 210 nm and 292 nm traces, three fragments were chosen for sequence analysis: T90, T94, and T92. Guess-mer oligomers were then synthesized based on the amino acid sequences of these fragments.

Figure 11(a) is the amino-terminal sequence obtained for RP-II fragment T90. A total of 15 residues were obtained, 67% of which have only one or two possible codons. The specificity of a probe (BRT90) constructed based on the sequence of fragment T90 was enhanced by the presence of a predicted tryptophan residue (position 12). The number in parentheses at each position represents the possible number of codons for each residue.

The amino-terminal sequence of RP-II fragment T94 is shown in Figure 11(b). Of the 30 residues determined, none were found to be tryptophan. Although only 36% of the residues (numbers 1-25) have two possible codons, the length of the corresponding 75-mer probe (707) renders it useful for corroborating hybridization experiments conducted with the T90 probe.

The third and final probe was constructed based on sequence information obtained from RP-II fragment T92 (Fig. 11(c)). Because of the relatively high degree of degeneracy at the beginning and end of this sequence, a probe was constructed based on residues 15-27. The resulting 39-mer probe (715) codes for a peptide of which half the residues have only one or two possible codons. Furthermore, the specificity of this probe was enhanced by the tandem location of a methionine and tryptophan residue at positions 26 and 27.

#### Cloning of RP-II

Chromosomal DNA was cut with various restriction enzymes and a series of hybridizations using the radiolabelled oligomer probes BRT90 and 707 were performed. Both probes were labelled with <sup>32</sup>P and hybridized to a Southern blot of GP241 DNA digested with *Bam*HI, *Bgl*II, *Hinc*II, *Pst*I, or *Eco*RI under semi-stringent conditions (5 x SSC, 10% formamide, 1 x Denhardt's, 100  $\mu$ g/ml denatured salmon sperm DNA at 37°C). After hybridization for 18 hours, the blots were washed with 2 x SSC, 0.1% SDS for one hour at 37°C, and then washed with the same buffer at 45°C for one hour. The results are shown in Fig. 12. Both probes hybridized to the same restriction fragments: *Hinc*II, ~1 kb;

PstI, 3-4 kb, and EcoRI, 6-7 kb. The probes also hybridized to very large fragments in the BamHI and BglII-digested DNAs.

PstI fragments of 3-4 kb were used to construct a DNA library, as follows. pBR322 was digested with PstI and treated with CIAP. Size-selected PstI-digested GP241 chromosomal DNA of 3-4.5 kb was electroeluted from a 0.8% agarose gel. Approximately 0.1 µg of PstI-cut pBR322 and 0.2 µg of the size-selected DNA was ligated at 16°C overnight. The ligated DNA was then transformed into *E. coli* DH5 cells. Approximately 10,000 colonies resulted, of which 60% contained plasmids with the insert DNA. 1400 colonies were patched onto LB plates containing 15 µg/ml tetracycline with nitrocellulose filters. After colonies were grown at 37°C overnight, the filters were processed to lyse the colonies, denature the DNA, and remove cell debris. The filters were then baked at 80° for two hours. Colony hybridization was performed using radiolabelled probe 707. Hybridization conditions were identical to those used in the Southern blot experiments. Analysis of the plasmid DNA from four positive colonies identified one as containing plasmid DNA that contained a 3.6 kb insert which strongly hybridized to both probes. The plasmid, pLP1, is shown in Fig. 13(b).

A restriction map of pLP1 (Fig. 13(a)) was constructed using a variety of restriction endonucleases to digest pLP1, transferring the size-fractionated digests onto nitrocellulose, and probing the immobilized restriction fragments with the radiolabelled oligomers described above. It was determined that all three oligomers, which encode a total of 53 amino acids within the RP-II protein, hybridized with the 1.1 kb HincII fragment.

The 1.1 kb HincII fragment was isolated and cloned into M13mp18. A phage clone containing the HincII fragment was identified by hybridization with one of the oligomer probes. The DNA sequence of the HincII fragment revealed an open reading frame that spanned most of the fragment (position -24 to position 939 in Figure 14). The most probable initiation codon for this open reading frame is the ATG at position 1 in Figure 14. This ATG is preceded by a *B. subtilis* ribosome binding site (AAAGGAGG), which has a calculated ΔG of -16.0 kcal. The first 33 amino acids following this Met resembled a *B. subtilis* signal sequence, with a short sequence containing four positively-charged amino acids, followed by 18 hydrophobic residues, a helix-breaking proline, and a typical Ala-X-Ala signal peptidase cleavage site. After the presumed signal peptidase cleavage site, a "pro" region of 58 residues is found, followed by the beginning of the mature protein as determined by the N-terminal amino acid sequence of the purified protein. The amino terminal 16 residues are underlined and designated "N terminus". Amino acid sequences from which the three guess-mers were deduced are also underlined and designated T94, T92, and T90. The determined amino acid sequences of the peptides matched the deduced amino acid sequence except for a serine residue encoded by nucleotides 379-381 and a cysteine residue encoded by nucleotides 391-393. The determined amino acid sequence predicted a cysteine residue (position 14, T94 peptide) and an asparagine residue (position 18, T94 peptide), respectively (Figure 11). The entire mature protein was deduced to contain 221 amino acids with a predicted molecular weight of 23,941 daltons. This size was in approximate agreement with the determined molecular weight of the purified protein, 28,000 daltons.

The deduced amino acid sequence showed only limited homology to other sequences in GENBANK. The strongest homology was to human protease E and bovine procarboxypeptidase A in a 25 amino acid sequence within RP-II (131-155, encoded by nucleotides 391-485; Figure 14).

To further confirm the identity of the RP-II gene, the 3.6 kb PstI fragment was engineered onto a multi-copy *Bacillus* replicon to test for overproduction of the RP-II protein. For this purpose the *Bacillus* plasmid pBs81/8 (Cm<sup>r</sup>, Neo<sup>r</sup>) was inserted into the *E. coli* clone containing the RP-II gene. Plasmid pLP1 (8.0 kb) was digested with EcoRI, which cuts at a single site outside the PstI insert, and ligated to EcoRI-digested pBs81/8 (4.5 kb; Fig. 13(a)). The resulting plasmid (pCR130) was used to transform GP241, and chloramphenicol or neomycin-resistant transformants were selected. Supernatant samples from cultures of the transformants were found to contain 3-4 fold more azocoll-hydrolyzing activity than the supernatants from cells containing only the plasmid pBs81/8, indicating that the gene for RP-II is wholly contained within the 3.6 kb PstI fragment.

#### Location of the RP-II Gene on the *B. subtilis* chromosome

In order to map the RP-II gene (*mpr*) on the *B. subtilis* chromosome, we used *B. subtilis* strain GP261 described below which contained the *cat* gene inserted into the chromosome at the site of the *mpr* gene and used phage PBS1 transduction to determine the location of the *cat* insertion.

Mapping experiments indicated that the inserted *cat* gene and *mpr* were linked to *cysA*14 (7% co-transduction) and to *aro*1906 (36% co-transduction) but unlinked to *purA*16 and *dal*. This data indicated that the *mpr* gene was between *cysA* and *aro*1 in an area of the genetic map not previously known to contain protease genes.

#### Deletion of the RP-II Gene on the *Bacillus* Chromosome

As described above for the other *Bacillus subtilis* proteases, an RP-II *Bacillus* deletion mutant was constructed by substituting a deleted version of the RP-II gene for the complete copy on the chromosome. To ensure the deletion of the entire RP-II gene, a region of DNA was deleted between the two HpaI sites in the insert (Fig. 13(a)). This region

contains the entire 1.1 kb HincII fragment and an additional 0.9 kb of DNA upstream of the HincII fragment.

To create the deletion, plasmid pLP1 (the pBR322 clone containing the 3.6 kb PstI fragment) was digested with HpaI and size-fractionated on an agarose gel. Digestion of pLP1 results in the release of the 2-kb internal HpaI-fragment and a larger HpaI fragment containing the vector backbone and segments that flank the PstI insert (Fig. 13(c)). The larger HpaI fragment was purified and ligated with purified blunt-ended DNA fragments containing either the chloramphenicol-resistance (cat) gene from pMI1101 (Youngman et al., 1984, *supra*) or the bleomycin resistance (ble) gene from pKT4, a derivative of pUB110 (available from the Bacillus Stock Center, Columbus Ohio).

The cat gene was isolated as a 1.6 kb SmaI fragment from pEcc1. This DNA was ligated to the isolated large HpaI fragment of pLP1. The ligated DNA was then transformed into *E. coli* DH5 cells. Approximately 20 Tetr colonies resulted. One colony was found to be Cm<sup>r</sup> when the colonies were patched onto LB medium + 5 µg/ml chloramphenicol. Analysis

of the plasmid DNA from this colony confirmed the presence of the cat gene. This plasmid was called pLP2.

Plasmid pLP2 (Fig. 13(c)) was digested with PstI and then transformed into GP241. This transformation gave approximately 280 Cm<sup>r</sup> colonies; one colony was chosen for further study (GP261). Competent cells of GP261 were prepared and then transformed with pDP104 (sacQ<sup>+</sup>); 10 Tetr colonies resulted. Four colonies were grown in MRS medium and the presence of sacQ<sup>+</sup> was confirmed by elevated levels of aminopeptidase. This strain was called GP262.

Since the cat gene was often used to select other vectors, a different antibiotic resistance was also used to mark the deletion of the RP-II gene on the *Bacillus* chromosome; i.e., the bleomycin-resistance gene of pUB110. The ble gene was isolated from plasmid pKT4, a derivative of pUB110, as an EcoRV-SmaI fragment and ligated to the purified large HpaI fragment (Fig. 13(c)) before transformation into *E. coli* DH5 cells; tetracycline-resistant transformants were selected and then screened for resistance to phleomycin, a derivative of bleomycin, by patching onto TBAB plates containing phleomycin at a final concentration of 2 µg/ml. Of 47 Tetr transformants so screened, seven were also these clones. The insertion of the ble gene was confirmed by restriction analysis of the plasmids isolated from these clones. One of these plasmids, pCR125 (Fig. 13(c)), was used to introduce the deleted gene containing the ble gene marker into the strain GP241 by gene replacement methods, as described below.

Plasmid pCR125 was digested with EcoRI and the linear plasmid DNA was used to transform GP241 to phleomycin resistance. Resistant transformants were selected by plating the transformed cells onto TBAB agar plates containing a gradient of 0-5 µg/ml phleomycin across the plate. Transformants that were resistant to approximately 2.5 µg/ml phleomycin on the plates were single-colony purified on TBAB phleomycin plates and thereafter grown on TBAB without selective antibiotic (strain GP263).

The strains bearing the RP-II deletion and the cat or ble insertion in the RP-II gene, along with the positive regulatory element, sacQ<sup>+</sup>, were evaluated for extracellular enzyme production, particularly protease and esterase activities.

The data given in Table 1, below, indicate that the presence of sacQ<sup>+</sup> in *B. subtilis* strain GP239, which bears null mutations in the five protease genes apr (subtilisin), npr (neutral protease), gpr (extracellular protease), isp (internal serine protease), and bpr, enhanced production of the RP-II protease (which also has esterase activity). To assess the influence on protease production of deleting RP-II from strains of *B. subtilis* bearing the sacQ<sup>+</sup> regulatory element, the following experiments were performed.

Independent clones of the RP-II deletion strain GP262 were shown to produce negligible amounts of esterase activity and no detectable levels of endoprotease activity using azocoll as substrate (Table I). To confirm the absence of protease activity, culture supernatants from GP262 were concentrated to the extent that the equivalent of 1 ml of supernatant could be assayed. Even after 2.5 hours incubation of the equivalent of 1 ml of supernatant with the azocoll substrate, there was no detectable protease activity in the deleted RP-II strain. By comparison, 50 µl of supernatant from GP239 typically gave an A<sub>520</sub> in the azocoll assay of over 2.0 after a one hour incubation at 55°C. (The presence of sacQ<sup>+</sup> was confirmed by measurement of the levels of aminopeptidase present in the culture fluids of this strain, which were 50-80 fold higher than in analogous strains lacking sacQ<sup>+</sup>.) Thus, deletion of the two residual proteases, RP-I and RP-II, in *Bacillus* yields a strain that is largely incapable of producing extracellular endoproteases, as measured using azocoll as a substrate under the conditions described above.

Table 1

Strain	Aminopeptidase	Protease	Esterase
	(U/ml)	(U/ml)	(U/ml)
GP238	0.04	0.13	0.02
GP239	1.7	84	1.16
GP262, AI	2.9	ND	0.08
GP262, AII	3.4	ND	0.11
GP262, BI	1.9	ND	0.10
GP262, BII	2.5	ND	0.10

Aminopeptidase was measured using L-I ucine-p-nitroanilide as substrat (1 unit =  $\mu$ moles substrate hydrolyzed/minute). Protease was measured using the standard azocoll assay (1 unit =  $\Delta A_{520}$  of 0.5/hour). Esterase was measured using N-t-BOC-glutamic acid- $\alpha$ -phenyl ester as substrate (1 unit =  $\mu$ moles substrate hydrolyzed/minute). Strain GP238 has the genotype  $\Delta apr$ ,  $\Delta npr$ ,  $\Delta epr$ ,  $\Delta isp$ ,  $\Delta rg-1$ ; strain GP239 has th genotype  $\Delta apr$ ,  $\Delta npr$ ,  $\Delta epr$ ,  $\Delta isp$ ,  $\Delta rg-1$ ,  $\Delta sacQ^+$ ; and GP262 AI, All, BI, and BII ar independent clones of GP262 containing  $\Delta sacQ^+$  and a cat insertional deletion in RP-II. ND means not detectable.

Referring to Table 2, several protease-deficient strains were also tested for pr tease activity using the more sensitive resorufin-labelled casein assay described earlier. As is shown in Table 2, although the strain GP263, deleted for six protease genes, exhibited no detectable protease activity in the azocoll test, such activity was detected in the resorufin-labelled casein test. GP271, the spoQA derivative of GP263, exhibited no detectable protease activity in either test, indicating that the prior protease activity detected in GP263 may be under sporulation control. The minor casein-detectable activity present in culture fluids of GP263 apparently belongs to the serine protease family, because of its sensitivity to inhibition by PMSF. In the presence of PMSF, no detectable protease activity was present in cultures of GP263.



**Table 2**

5

10

15

20

25

30

35

40

45

50

55

Remaining activity  
(% of wild-type at t<sub>20</sub>)

Strain	Genotype	1	2
IS75	Wild-type	100	100
GP202	$\Delta apr, \Delta npr, amyE$	5	8
GP208	$\Delta apr, \Delta npr, \Delta isp-1, amyE, met^-$	5	8
GP263	$\Delta apr, \Delta npr, \Delta isp-1, \Delta epr, \Delta bpr, \Delta mpr, \Delta hpr, amyE, met^-$	ND	0.5-1
GP271	$spoOA, \Delta apr, \Delta npr, \Delta isp-1, \Delta epr, \Delta bpr, \Delta mpr, \Delta hpr, amyE, met^-$	ND	ND

1 As measured using azocoll as substrate.

2 As measured using resorufin casein as substrate.

Other embodiments are feasible.

For example, in some instances it may be desirable to express, rather than mutate or delete, a gene or genes encoding protease(s).

This could be done, for example, to produce the proteases for purposes such as improvement of the cleaning activity of laundry detergents or for use in industrial processes. This can be accomplished either by inserting regulatory DNA (any appropriate *Bacillus* promoter and, if desired, ribosome binding site and/or signal encoding sequence) upstream of the protease-encoding gene or, alternatively, by inserting the protease-encoding gene into a *Bacillus* expression or secretion vector; the vector can then be transformed into a *Bacillus* strain for production (or secretion) of the protease, which is then isolated by conventional techniques. Alternatively, the protease can be overproduced by inserting one or more copies of the protease gene on a vector into a host strain containing a regulatory gene such as *sacQ*.

Claims

1. A Bacillus cell characterised in containing a mutation in the epi gene, said epi gene encoding a protein comprising the amino acid sequence of Figure 6 or an evolutionary homologue thereof of other Bacillus species, having protease activity, said mutation resulting in inhibition of the production by said cell of proteolytically active epi gene product.
2. A Bacillus cell according to Claim 1, characterised in further containing a mutation in the RP-I-encoding gene, said RP-I encoding gene encoding a protein comprising the amino acid sequence of Figure 10 or an evolutionary homologue thereof of other Bacillus species, having protease activity, said mutation resulting in inhibition of the production by said cell of proteolytically active RP-I.
3. A Bacillus cell characterised in containing a mutation in the RP-I-encoding gene, said RP-I encoding gene encoding a protein comprising the amino acid sequence of Figure 10 or an evolutionary homologue thereof of other Bacillus species, having protease activity, said mutation resulting in inhibition of the production by said cell of proteolytically active RP-I.
4. A Bacillus cell according to any preceding claim, characterised in further containing a mutation in the RP-II encoding gene, said RP-II encoding gene encoding a protein comprising the amino acid sequence of Figure 14 or an evolutionary homologue thereof of other Bacillus species, having protease activity, said mutation resulting in inhibition of the production by said cell of proteolytically active RP-II.
5. A Bacillus cell characterised in containing a mutation in the RP-II-encoding gene, said RP-II encoding gene encoding a protein comprising the amino acid sequence of Figure 14 or an evolutionary homologue thereof of other Bacillus species, having protease activity, said mutation resulting in inhibition of the production by said cell of proteolytically active RP-II.
6. A Bacillus cell according to any preceding claim, characterised in further containing mutations in the epi and npr genes encoding extracellular proteases, said mutations resulting in inhibition of the production by said cell of said encoded proteolytic activities.
7. A Bacillus cell according to any preceding Claim, further characterised in that the or each said mutation comprises a deletion within the coding region of the gene.
8. A Bacillus cell according to any preceding claim, further containing a mutation in the isp-1 gene encoding an intracellular protease, said mutation resulting in inhibition of production by said cell of proteolytically active isp-1 gene product.
9. A Bacillus cell according to any of Claims 1 to 7, characterised in further containing a mutation which reduces said cell's capacity to produce one or more sporulation-dependent proteases.
10. A Bacillus cell according to Claim 9, further characterised in that said sporulation-dependent protease mutation blocks sporulation at an early stage but does not eliminate the cell's ability to be transformed by purified DNA.
11. A Bacillus cell according to Claim 10, further characterised in that said sporulation-dependent protease mutation is in the spoOA gene.
12. A Bacillus cell according to any preceding claim, further characterised in being a Bacillus subtilis cell.
13. A Bacillus cell according to any preceding claim, characterised in further comprising a gene encoding a heterologous polypeptide.
14. A cell according to Claim 13, further characterised in that said heterologous polypeptide is a hormone, vaccine, antiviral protein, antitumour protein, antibody or clotting protein.
15. A cell according to Claim 13, further characterised in that said heterologous polypeptide is a pesticide or enzyme.
16. A method for producing a heterologous polypeptide in a Bacillus cell, characterised in comprising: introducing into

said cell a gene encoding said heterologous polypeptide, modified to be expressed in said cell, said Bacillus cell containing mutations in the epr and npr genes, and further containing mutations in one or more of the genes encoding the Epr protease, RP-I, or RP-II, said Epr, RP-I and RP-II comprising the amino acid sequences set out in Figures 6, 10 and 14 respectively, or evolutionary homologues thereof of other Bacillus species, having protease activity, wherein said mutation results in the inhibition of the production by said cell of proteolytically active Epr protease, RP-I or RP-II.

17. A method according to Claim 16, characterised in further containing a mutation in the isp-1 gene encoding intracellular protease I, said mutation resulting in inhibition of production by said cell of proteolytically active isp-1 gene product.
18. A method according to Claims 16 or 17, further characterised in that said heterologous polypeptide is normally unstable in a Bacillus cell.
19. A method according to any of Claims 16, 17 or 18, further characterised in that said cell is a Bacillus subtilis cell.
20. A method according to any of Claims 16 to 19, further characterised in that said cell further contains a mutation which reduces said cell's capacity to produce one or more sporulation-dependent proteases, said mutation being in the spoOA gene.
21. A method according to any of Claims 16 to 20, further characterised in that said heterologous polypeptide is a hormone, vaccine, antiviral protein, antitumour protein, antibody, clotting protein, pesticide or enzyme.
22. Purified DNA comprising a Bacillus epr gene, said gene encoding the amino acid sequence of Figure 6 or an evolutionary homologue thereof of other Bacillus species, having protease activity.
23. Purified DNA comprising a Bacillus gene encoding RP-I, said gene encoding the amino acid sequence of Figure 10 or an evolutionary homologue thereof of other Bacillus species, having protease activity.
24. Purified DNA comprising a Bacillus gene encoding RP-II, said gene encoding the amino acid sequence of Figure 14 or an evolutionary homologue thereof of other Bacillus species, having protease activity.
25. A vector comprising a Bacillus epr gene, said gene encoding the amino acid sequence of Figure 6 or an evolutionary homologue thereof of other Bacillus species, having protease activity, and regulatory DNA operationally associated with said gene.
26. A vector comprising a Bacillus gene encoding, RP-I said gene encoding the amino acid sequence of Figure 10 or an evolutionary homologue thereof of other Bacillus species, having protease activity, and regulatory DNA operationally associated with said gene.
27. A vector comprising a Bacillus gene encoding, RP-II said gene encoding the amino acid sequence of Figure 14 or an evolutionary homologue thereof of other Bacillus species, having protease activity, and regulatory DNA operationally associated with said gene.
28. A Bacillus cell transformed with a vector according to any of Claims 25, 26 and 27.
29. Substantially pure Bacillus Epr protease comprising the amino acid sequence of Figure 6 or an evolutionary homologue thereof of other Bacillus species, having protease activity.
30. Substantially pure Bacillus residual protease I (RP-I) comprising the amino acid sequence of Figure 10 or an evolutionary homologue thereof of other Bacillus species, having protease activity.
31. Substantially pure Bacillus residual protease II (RP-II) comprising the amino acid sequence of Figure 14 or an evolutionary homologue thereof of other Bacillus species, having protease activity.

## Patentansprüche

1. Bacillus-Zelle, dadurch gekennzeichnet, daß sie eine Mutation im epr-Gen enthält, wobei das pr-Gen für ein Protein, das die Aminosäuresequenz aus Figur 6 umfaßt oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert, und die Mutation zur Inhibition der Produktion des proteolytisch aktiven epr-Genprodukts durch diese Zelle führt.
2. Bacillus-Zelle nach Anspruch 1, dadurch gekennzeichnet, daß sie weiterhin eine Mutation im für die RP-I kodierenden Gen enthält, wobei das für die RP-I kodierende Gen für ein Protein, das die Aminosäuresequenz von Figur 10 umfaßt oder ein anderes evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert, und die Mutation zur Inhibition der Produktion von proteolytisch aktivem RP-I durch diese Zelle führt.
3. Bacillus-Zelle, dadurch gekennzeichnet, daß sie eine Mutation im für die RP-I kodierenden Gen enthält, wobei das für die RP-I kodierende Gen für ein Protein, das die Aminosäuresequenz von Figur 10 umfaßt oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert, und die Mutation zur Inhibition der Produktion von proteolytisch aktivem RP-I durch diese Zelle führt.
4. Bacillus-Zelle nach einem der vorangegangenen Ansprüche, dadurch gekennzeichnet, daß sie weiterhin eine Mutation im für die RP-II kodierenden Gen enthält, wobei das für die RP-II kodierende Gen für ein Protein, das die Aminosäuresequenz von Figur 14 umfaßt oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert, und die Mutation zur Inhibition der Produktion von proteolytisch aktivem RP-II durch diese Zelle führt.
5. Bacillus-Zelle, dadurch gekennzeichnet, daß sie eine Mutation im für die RP-II kodierenden Gen enthält, wobei das für die RP-II kodierende Gen für ein Protein, das die Aminosäuresequenz von Figur 14 umfaßt oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert, und die Mutation zur Inhibition der Produktion von proteolytisch aktivem RP-II durch diese Zelle führt.
6. Bacillus-Zelle nach einem der vorangegangenen Ansprüche, dadurch gekennzeichnet, daß sie weiterhin Mutationen in den für extrazelluläre Proteasen kodierenden apr- und npr-Genen enthält, und die Mutationen zur Inhibition der Produktion dieser kodierten proteolytischen Aktivitäten durch diese Zelle führen.
7. Bacillus-Zelle nach einem der vorangegangenen Ansprüche, dadurch gekennzeichnet, daß außerdem die Mutation oder jede dieser Mutationen eine Deletion innerhalb der kodierenden Region des Gens enthält.
8. Bacillus-Zelle nach einem der vorangegangenen Ansprüche, dadurch gekennzeichnet, daß sie weiterhin eine Mutation im für eine intrazelluläre Protease kodierenden isp-1-Gen enthält und die Mutation zur Inhibition des proteolytisch aktiven isp-1-Genprodukts durch diese Zelle führt.
9. Bacillus-Zelle nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß sie außerdem eine Mutation enthält, die die Fähigkeit der Zelle, eine oder mehrere sporenbildungsabhängige Protease(n) zu produzieren, herabsetzt.
10. Bacillus-Zelle nach Anspruch 9, dadurch gekennzeichnet, daß weiterhin die Mutation der sporenbildungsabhängigen Protease die Sporenbildung in einem frühen Stadium blockiert, jedoch nicht die Fähigkeit der Zelle, mit gereinigter DNA transformiert zu werden, ausschaltet.
11. Bacillus-Zelle nach Anspruch 10, dadurch gekennzeichnet, daß sich weiterhin die Mutation der sporenbildungsabhängigen Protease im spoOA-Gen befindet.
12. Bacillus-Zelle nach einem der vorangegangenen Ansprüche, dadurch gekennzeichnet, daß sie des weiteren eine Bacillus subtilis-Zelle ist.
13. Bacillus-Zelle nach einem der vorangegangenen Ansprüche, dadurch gekennzeichnet, daß sie weiterhin ein für ein heterologes Polypeptid kodierendes Gen enthält.
14. Zelle nach Anspruch 13, dadurch gekennzeichnet, daß das heterologe Polypeptid ein Hormon, Vakzin, antivirales Protein, Antitumorprotein, Antikörper oder Gerinnungsprotein darstellt.

15. Zelle nach Anspruch 13, dadurch gekennzeichnet, daß das heterologe Polypeptid in Pestizid oder Enzym darstellt.

16. Verfahren zur Herstellung eines heterologen Polypeptids in einer Bacillus-Zelle, dadurch gekennzeichnet, daß man in diese Zelle ein für das heterologe Polypeptid kodierendes Gen, das für die Expression in dieser Zelle modifiziert ist, einführt, wobei die Bacillus-Zelle in den apr- und npr-Genen Mutationen enthält und außerdem Mutationen in einem oder mehreren Gen(en), die das für die epr-Protease, RP-I oder RP-II kodiert bzw. kodieren, enthalten sind, und die Epr, RP-I und RP-II die Aminosäuresequenzen aus den Figuren 6, 10 bzw. 14 oder evolutionäre Homologe davon von anderen Bacillus-Spezies mit Protease-Aktivität umfassen, und die Mutation zur Inhibierung der Produktion von proteolytisch aktiver Epr-Protease, RP-I oder RP-II durch diese Zelle führt.

17. Verfahren nach Anspruch 16, dadurch gekennzeichnet, daß weiterhin eine Mutation im für eine intrazelluläre Protease-I kodierenden isp-1 Gen vorhanden ist, und die Mutation zur Inhibierung der Produktion von proteolytisch aktivem isp-1 Genprodukt durch diese Zelle führt.

18. Verfahren nach Anspruch 16 oder 17, dadurch gekennzeichnet, daß weiterhin das heterologe Polypeptid in einer Bacillus-Zelle normalerweise instabil ist.

19. Verfahren nach einem der Ansprüche 16, 17 oder 18, dadurch gekennzeichnet, daß die Zelle eine Bacillus subtilis-Zelle ist.

20. Verfahren nach einem der Ansprüche 16 bis 19, dadurch gekennzeichnet, daß die Zelle außerdem eine Mutation enthält, die das Vermögen der Zelle, eine oder mehrere sporenbildungsabhängige Protease(n) zu produzieren, herabsetzt, wobei sich die Mutation im spoOA-Gen befindet.

21. Verfahren nach einem der Ansprüche 16 bis 20, dadurch gekennzeichnet, daß das heterologe Polypeptid ein Hormon, Vakzin, antivirales Protein, Antitumorprotein, Antikörper, Gerinnungsprotein, Pestizid oder Enzym darstellt.

22. Gereinigte DNA mit einem epr-Gen aus Bacillus, worin das Gen für die Aminosäuresequenz von Figur 6 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert.

23. Gereinigte DNA mit einem für die RP-I kodierenden Bacillus-Gen, worin dieses Gen für die Aminosäuresequenz von Figur 10 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert.

24. Gereinigte DNA mit einem für die RP-II kodierenden Bacillus-Gen, worin das Gen für die Aminosäuresequenz von Figur 14 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert.

25. Vektor mit einem epr-Gen aus Bacillus, worin das Gen für die Aminosäuresequenz von Figur 6 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert und regulatorischen DNA-Elementen, die funktionell mit diesem Gen verbunden sind.

26. Vektor mit einem für die RP-I kodierenden Bacillus-Gen, worin das Gen für die Aminosäuresequenz von Figur 10 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert und anderen regulatorischen DNA-Elementen, die funktionell mit diesem Gen verbunden sind.

27. Vektor mit einem für die RP-II kodierenden Bacillus-Gen, worin das Gen für die Aminosäuresequenz von Figur 14 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität kodiert und anderen regulatorischen DNA-Elementen, die funktionell mit diesem Gen verbunden sind.

28. Bacillus-Zelle, die mit einem Vektor nach einem der Ansprüche 25, 26 und 27 transformiert ist.

29. Im wesentlichen reine Epr-Protease aus Bacillus, die die Aminosäuresequenz von Figur 6 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität umfaßt.

30. Im wesentlichen reine Restprotease I (RP-I) aus Bacillus, die die Aminosäuresequenz von Figur 10 oder ein evolutionäres Homologes davon von anderen Bacillus-Spezies mit Protease-Aktivität umfaßt.

31. Im wesentlichen reine Restprotease II (RP-II) aus Bacillus, die die Aminosäuresequenz von Figur 14 oder ein evolutionäres Homologes davon von einer Bacillus-Spezies mit Protease-Aktivität umfaßt.

## 5 R revendications

1. Cellule de Bacillus caractérisée en ce qu'elle contient une mutation dans le gène epr, ledit gène epr codant une protéine comprenant la séquence d'acides aminés de la figure 6 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, ladite mutation entraînant une inhibition de la production par ladite cellule d'un produit du gène epr actif du point de vue protéolytique.
2. Cellule de Bacillus selon la revendication 1, caractérisée en ce qu'elle contient en outre une mutation dans le gène codant la RP-I, ledit gène codant la RP-I codant une protéine comprenant la séquence d'acides aminés de la figure 10 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, ladite mutation entraînant l'inhibition de la production par ladite cellule d'une RP-I active du point de vue protéolytique.
3. Cellule de Bacillus caractérisée en ce qu'elle contient une mutation dans le gène codant la RP-I, ledit gène codant la RP-I codant une protéine comprenant la séquence d'acides aminés de la figure 10 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, ladite mutation entraînant l'inhibition de la production par ladite cellule d'une RP-I active du point de vue protéolytique.
4. Cellule de Bacillus selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle contient en outre une mutation dans le gène codant la RP-II, ledit gène codant la RP-II codant une protéine comprenant la séquence d'acides aminés de la figure 14 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, ladite mutation entraînant l'inhibition de la production par ladite cellule d'une RP-II active du point de vue protéolytique.
5. Cellule de Bacillus caractérisée en ce qu'elle contient une mutation dans le gène codant la RP-II, ledit gène codant la RP-II codant une protéine comprenant la séquence d'acides aminés de la figure 14 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, ladite mutation entraînant l'inhibition de la production par ladite cellule d'une RP-II active du point de vue protéolytique.
6. Cellule de Bacillus selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle contient en outre des mutations dans les gènes epr et npr codant des protéases extracellulaires, lesdites mutations entraînant l'inhibition de la production par ladite cellule desdites activités protéolytiques codées.
7. Cellule de Bacillus selon l'une quelconque des revendications précédentes, caractérisée en outre en ce que ladite mutation ou chacune desdites mutations comprend une délétion dans la région codante du gène.
8. Cellule de Bacillus selon l'une quelconque des revendications précédentes, comprenant en outre une mutation dans le gène isp-1 codant une protéase intracellulaire, ladite mutation entraînant l'inhibition de la production par ladite cellule d'un produit du gène isp-1 actif du point de vue protéolytique.
9. Cellule de Bacillus selon l'une quelconque des revendications 1 à 7, caractérisée en ce qu'elle contient en outre une mutation qui réduit la capacité de ladite cellule à produire une ou plusieurs protéases dépendantes de la sporulation.
10. Cellule de Bacillus selon la revendication 9, caractérisée en outre en ce que ladite mutation des protéases dépendantes de la sporulation bloque la sporulation à un stade précoce mais n'élimine pas l'aptitude de la cellule à être transformée par un ADN purifié.
11. Cellule de Bacillus selon la revendication 10, caractérisée en outre en ce que ladite mutation des protéases dépendantes de la sporulation est dans le gène spoOA.
12. Cellule de Bacillus selon l'une quelconque des revendications précédentes, caractérisée en outre en ce qu'il s'agit d'une cellule de Bacillus subtilis.
13. Cellule de Bacillus selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend

en outre un gène codant un polypeptide hétérologue.

14. Cellule selon la revendication 13, caractérisée en outre en ce que ledit polypeptide hétérologue est une hormone, un vaccin, un protéin antivirale, une protéine antitumorale, un anticorps ou une protéine de coagulation.
15. Cellule selon la revendication 13, caractérisée en outre en ce que ledit polypeptide hétérologue est un pesticide ou une enzyme.
16. Procédé de production d'un polypeptide hétérologue dans une cellule de Bacillus, caractérisé en ce qu'il comprend : l'introduction dans ladite cellule d'un gène codant ledit polypeptide hétérologue, modifié pour être exprimé dans ladite cellule, ladite cellule de Bacillus contenant des mutations dans les gènes apr et npr, et contenant en outre des mutations dans un ou plusieurs des gènes codant la protéase Epr, RP-I ou RP-II, lesdites Epr, RP-I et RP-II comprenant les séquences d'acides aminés représentées sur les figures 6, 10 et 14 respectivement, ou des homologues évolutifs de celles-ci d'autres espèces de Bacillus ayant une activité de protéase, ladite mutation entraînant l'inhibition de la production par ladite cellule de protéase Epr, de RP-I ou de RP-II active du point de vue protéolytique.
17. Procédé selon la revendication 16, caractérisé en ce qu'il comprend en outre une mutation dans le gène isp-1 codant la protéase intracellulaire I, ladite mutation entraînant l'inhibition de la production par ladite cellule d'un produit du gène isp-1 actif du point de vue protéolytique.
18. Procédé selon les revendications 16 ou 17, caractérisé en outre en ce que ledit polypeptide hétérologue est normalement instable dans une cellule de Bacillus.
19. Procédé selon l'une quelconque des revendications 16, 17 ou 18, caractérisé en outre en ce que ladite cellule est une cellule de Bacillus subtilis.
20. Procédé selon l'une quelconque des revendications 16 à 19, caractérisé en outre en ce que ladite cellule contient en outre une mutation qui réduit la capacité de ladite cellule à produire une ou plusieurs protéases dépendantes de la sporulation, ladite mutation étant dans le gène spoOA.
21. Procédé selon l'une quelconque des revendications 16 à 20, caractérisé en outre en ce que ledit polypeptide hétérologue est une hormone, un vaccin, une protéine antivirale, une protéine antitumorale, un anticorps, une protéine de coagulation, un pesticide ou une enzyme.
22. ADN purifié comprenant un gène epr de Bacillus, ledit gène codant la séquence d'acides aminés de la figure 6 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase.
23. ADN purifié comprenant un gène de Bacillus codant RP-I, ledit gène codant la séquence d'acides aminés de la figure 10 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase.
24. ADN purifié comprenant un gène de Bacillus codant RP-II, ledit gène codant la séquence d'acides aminés de la figure 14 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase.
25. Vecteur comprenant un gène epr de Bacillus ledit gène codant la séquence d'acides aminés de la figure 6 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, et un ADN régulateur associé de manière active audit gène.
26. Vecteur comprenant un gène de Bacillus codant RP-I, ledit gène codant la séquence d'acides aminés de la figure 10 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, et un ADN régulateur associé de manière active audit gène.
27. Vecteur comprenant un gène de Bacillus codant RP-II, ledit gène codant la séquence d'acides aminés de la figure 14 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase, et un ADN régulateur associé de manière active audit gène.
28. Cellule de Bacillus transformée avec un vecteur selon l'une quelconque des revendications 25, 26 et 27.

29. Protéase Epr de Bacillus sensiblement pure comprenant la séquence d'acides aminés de la figure 6 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase.
- 5 30. Protéase résiduelle I (RP-I) de Bacillus sensiblement pure comprenant la séquence d'acides aminés de la figure 10 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase.
31. Protéase résiduelle II (RP-II) de Bacillus sensiblement pure comprenant la séquence d'acides aminés de la figure 14 ou un homologue évolutif de celle-ci d'autres espèces de Bacillus, ayant une activité de protéase.

10

15

20

25

30

35

40


45

50

55



FIG. 1



IS75NΔ IS75

2.4 Kb \_\_\_\_\_  
1.8 Kb \_\_\_\_\_


**FIG. 2**

**A. Probe BRT90**

**B. Probe 707**


*HincII*  
*PstI*  
*EcoRI*

*HincII*  
*PstI*  
*EcoRI*



**FIG. 12**

FIG. 3







FIG. 4

FIG. 5



## FIG. 6-1

-446 ATCCGAGCTTATCGGCCCACTCGTTCCCAACACACTCGCCATGAAATCAGCATACCC  
 GGAATCGGCAAGCTCGTTAAATCAAGAAGACAGCCGATAATAATCAGCGGCATGGT  
 CAGGATAATCCGTCACGCAAGCGCTGAGATGCCGCTGCCCGGCAATTTCCCGGCGAC  
 AGGCATTATTTTTCTCCATCACCCGAGTGAATGTGCTCATCTTAAAAACCCCTTTT  
 CTCATTGCTTTGTGAACAACCTCCGCAATGTTTTCTTTATCTTATTTGAAAACGCTTA  
 CAAATTCATTTGAAAAATTTCTCTTCATGCGGAAAAATCTGCATTTTGCTAAACAAC  
 CCTGCCCATGAAAAATTTTCTTCTTACTATTAATCTCTCTTTTTTCTCCGATATA  
 TATATCAAACATCATAGAAAGGAGTGAATC

+1 ATG AAA AAC ATG TCT TGC AAA CTT GTT GTA TCA GTC ACT CTG TTT  
*met lys asn met ser cys lys leu val val ser val thr leu phe*

46 TTC AGT TTT CTC ACC ATA GGC CCT CTC GCT CAT GCG CAA AAC AGC  
*phe ser phe leu thr ile gly pro leu ala his ala gln asn ser*

91 AGC GAG AAA GAG GTT ATT GTG GTT TAT AAA AAC AAG GCC GGA AAG  
*ser glu lys glu val ile val val tyr lys asn lys ala gly lys*

136 GAA ACC ATC CTG GAC AGT GAT GCT GAT GTT GAA CAG CAG TAT AAG  
*glu thr ile leu asp ser asp ala asp val glu gln gln tyr lys*

161 CAT CTT CCC GCG GTA GCG GTC ACA GCA GAC CAG GAG ACA GTA AAA  
*his leu pro ala val ala val thr ala asp gln glu thr val lys*

BamHI

226 GAA TTA AAG CAG GAT CCT GAT ATT TTG TAT GTA GAA AAC AAC GTA  
*glu leu lys gln asp pro asp ile leu tyr val glu asn asn val*

271 TCA TTT ACC GCA GCA GAC AGC ACG GAT TTC AAA GTG CTG TCA GAC  
*ser phe thr ala ala asp ser thr asp phe lys val leu ser asp*

316 GGC ACT GAC ACC TCT GAC AAC TTT GAG CAA TGG AAC CTT GAG CCC  
*gly thr asp thr ser asp asn phe glu gln trp asn leu glu pro*

361 ATT CAG GTG AAA CAG GCT TGG AAG GCA GGA CTG ACA GGA AAA AAT  
*ile gln val lys gln ala trp lys ala gly leu thr gly lys asn*

**FIG. 6-2**

406 ATC AAA ATT GCC GTC ATT GAC AGC GGG ATC TCC CCC CAC GAT GAC  
     ile lys ile ala val ile asp ser gly ile ser pro his asp asp  
 451 CTG TCG ATT GCC GGC GGG TAT TCA GCT GTC AGT TAT ACC TCT TCT  
     leu ser ile ala gly gly tyr ser ala val ser tyr thr ser ser  
 496 TAC AAA GAT GAT AAC GGC CAC GGA ACA CAT GTC GCA GGG ATT ATC  
     tyr lys asp asp asn gly his gly thr his val ala gly ile ile  
 541 GGA GCC AAG CAT AAC GGC TAC GGA ATT GAC GGC ATC GCA CCG GAA  
     gly ala lys his asn gly tyr gly ile asp gly ile ala pro glu  
 586 GCA CAA ATA TAC GCG GTT AAA GCG CTT GAT CAG AAC GGC TCG GGG  
     ala gln ile tyr ala val lys ala leu asp gln asn gly ser gly  
 631 GAT CTT CAA AGT CTT CTC CAA GGA ATT GAC TGG TCG ATC GCA AAC  
     asp leu gln ser leu leu gln gly ile asp trp ser ile ala asn  
 676 AGG ATG GAC ATC GTC AAT ATG AGC CTT GGC ACG ACG TCA GAC AGC  
     arg met asp ile val asn met ser leu gly thr thr ser asp ser  
 721 AAA ATC CTT CAT GAC GCC GTG AAC AAA GCA TAT GAA CAA GGT GTT  
     lys ile leu his asp ala val asn lys ala tyr glu gln gly val  
 766 CTG CTT GTT GCC GCA AGC GGT AAC GAC GGA AAC GGC AAG CCA GTG  
     leu leu val ala ala ser gly asn asp gly asn gly lys pro val  
 811 AAT TAT CCG GCG GCA TAC AGC AGT GTC GTT GCG GTT TCA GCA ACA  
     asn tyr pro ala ala tyr ser ser val val ala val ser ala thr  
 856 AAC GAA AAG AAT CAG CTT GCC TCC TTT TCA ACA ACT GGA GAT GAA  
     asn glu lys asn gln leu ala ser phe ser thr thr gly asp glu  
 901 GTT GAA TTT TCA GCA CCG GGG ACA AAC ATC ACA AGC ACT TAC TTA  
     val glu phe ser ala pro gly thr asn-ile thr ser thr tyr leu


## FIG. 6-3

946 AAC CAG TAT TAT GCA ACG GGA AGC GGA ACA TCC CAA GCG ACA CCG  
 asn gln tyr tyr ala thr gly ser gly thr ser gln ala thr pro  
 991 CAC GCC GCT GCC ATG TTT GCC TTG TTA AAA CAG CGT GAT CCT GCC  
 his ala ala ala met phe ala leu leu lys gln arg asp pro ala  
 1036 GAG ACA AAC GTC CAG CTT CGC GAG GAA ATG CCG AAA AAC ATC GTT  
 glu thr asn val gln leu arg glu glu met arg lys asn ile val  
KpnI  
 1081 GAT CTT GGT ACC GCA GGC CGC GAT CAG CAA TTT GGC TAC GGC TTA  
 asp leu gly thr ala gly arg asp gln gln phe gly tyr gly leu  
 1126 ATC CAG TAT AAA GCA CAG GCA ACA GAT TCA GCG TAC GCG GCA GCA  
 ile gln tyr lys ala gln ala thr asp ser ala tyr ala ala ala  
 1171 GAG CAA GCG GTG AAA AAA GCG GAA CAA ACA AAA GCA CAA ATC GAT  
 glu gln ala val lys lys ala glu gln thr lys ala gln ile asp  
EcoRV  
 1216 ATC AAC AAA GCG CGA GAA CTC ATC AGC CAG CTG CCG AAC TCC GAC  
 ile asn lys ala arg glu leu ile ser gln leu pro asn ser asp  
 1261 GCC AAA ACT GCC CTG CAC AAA AGA CTG GAT AAA GTA CAG TCA TAC  
 ala lys thr ala leu his lys arg leu asp lys val gln ser tyr  
 1306 AGA AAT GTA AAA GAT GCG AAA GAC AAA GTC GCA AAG GCA GAA AAA  
 arg asn val lys asp ala lys asp lys val ala lys ala glu lys  
 1351 TAT AAA ACA CAG CAA ACC GTT GAC ACA GCA CAA ACT GCC ATC AAC  
 tyr lys thr gln gln thr val asp thr ala gln thr ala ile asn  
 1396 AAG CTG CCA AAC GGA ACA GAC AAA AAG AAC CTT CAA AAA CGC TTA  
 lys leu pro asn gly thr asp lys lys asn leu gln lys arg leu  
 1441 GAC CAA GTA AAA CGA TAC ATC GCG TCA AAG CAA GCG AAA GAC AAA  
 asp gln val lys arg tyr ile ala ser lys gln ala lys asp lys



## FIG. 6-4

1486 GTT GCG AAA GCG GAA AAA AGC AAA AAG AAA ACA GAT GTG GAC AGC  
 val ala lys ala glu lys ser lys lys lys thr asp val asp ser  
  
 1531 GCA CAA TCA GCA ATT GGC AAG CTG CCT GCA AGT TCA GAA AAA ACG  
 ala gln ser ala ile gly lys leu pro ala ser ser glu lys thr  
PstI  
 1576 TCC CTG CAG AAA CGC CTT AAC AAA GTG AAG AGC ACC AAT TTG AAG  
 ser leu gln lys arg leu asn lys val lys ser thr asn leu lys  
  
 1621 ACG GCA CAG CAA TCC GTA TCT GCG GCT GAA AAG AAA TCA ACT GAT  
 thr ala gln gln ser val ser ala ala glu lys lys ser thr asp  
  
 1666 GCA AAT GCG GCA AAA GCA CAA TCA GCC GTC AAT CAG CTT CAA GCA  
 ala asn ala ala lys ala gln ser ala val asn gln leu gln ala  
  
 1711 GGC AAG GAC AAA ACG GCA TTG CAA AAA CGG TTA GAC AAA GTG AAG  
 gly lys asp lys thr ala leu gln lys arg leu asp lys val lys  
  
 1756 AAA AAG GTG GCG GCG GCT GAA GCA AAA AAA GTG GAA ACT GCA AAG  
 lys lys val ala ala ala glu ala lys lys val glu thr ala lys  
  
 1801 GCA AAA GTG AAG AAA GCG GAA AAA GAC AAA ACA AAG AAA TCA AAG  
 ala lys val lys lys ala glu lys asp lys thr lys lys ser lys  
PstI  
 1846 ACA TCC GCT CAG TCT GCA GTG AAT CAA TTA AAA GCA TCC AAT GAA  
 thr ser ala gln ser ala val asn gln leu lys ala ser asn glu  
  
 1891 AAA ACA AAG CTG CAA AAA CGG CTG AAC GCC GTC AAA CCG AAA  
 lys thr lys leu gln lys arg leu asn ala val lys pro lys  
  
 1936 AAG TAA CCAAAAACCTTTAAGATTTCATTCCAAGTCITAAAGGTTTTTT  
 lys ...  
  
 1994 CATTCTAAGA



Position	2	3	4	5	6	7	8	9	10
5'	- ACA	- GAT	- GGA	- GTT	- GAA	- TGG	- AAT	- GTT	- GAT
	- Thr	- Asp	- Gly	- Val	- Glu	- Trp	- Asn	- Val	- Asp


  

11	12	13	14	15	16	17	18	19	20
CAA	- ATT	- GAT	- GCT	- CCG	- AAA	- GCT	- TGG	- GCT	- TTA
Gln	- Ile	- Asp	- Ala	- Pro	- Lys	- Ala	- Trp	- Ala	- Leu


  

21	22	23	24	25	26	27	28
GGA	- TAT	- GAT	- GGA	- ACA	- GGA	- ACA	- GTT
Gly	- Tyr	- Asp	- Gly	- Thr	- Gly	- Thr	- Val

FIG. 8

**FIG. 9**

The underlined portion is the approximate location of the RP-I gene on the *Pst*I fragment.

**FIG. 13a**

The shaded box represents the region to which the RP-II "guess-maps" hybridized.

## FIG. 10-1

-199 TAACAAACAGATAATTAGACCCATTTATTTTGTGAGATTTTATCATTTCATATATAT  
 GGAATTGAACGACACGAAACGACAATATCTGTAAATTCAGATTGTCTACAGTTAATA  
 TACAGCGATGTTCTGACAAACCATTCATTATTAAGGAGGACGACACTTTTTTTA  
 AAAAGCATGTTGAAAAAGGGGATGAAA

41 ATG AGG AAA AAA ACG AAA AAC AGA CTC ATC AGC TCT GTT TTA AGT  
 met arg lys lys thr lys asn arg leu ile ser ser val leu ser

46 ACA GTT GTC ATC AGT TCA CTG CTG TTT CCG GGA GCA GCC GGG GCA  
 thr val val ile ser ser leu leu phe pro gly ala ala gly ala

91 AGC AGT AAA GTC ACC TCA CCT TCT GTT AAA AAG GAG GTT CAA TCT  
 ser ser lys val thr ser pro ser val lys lys glu leu gln ser

136 GCG GAA TCC ATT CAA AAC AAG ATT TCG AGT TCA TTA AAG AAA AGC  
 ala glu ser ile gln asn lys ile ser ser ser leu lys lys ser

181 TTT AAA AAG AAA GAA AAA ACG ACT TTT CTG ATT AAA TTT AAA GAT  
 phe lys lys lys glu lys thr thr phe leu ile lys phe lys asp

226 CTG GCT AAC CCA GAA AAA GCG GCA AAA GCG GCT GTT AAA AAA GCG  
 leu ala asn pro-glu lys ala ala lys ala ala val lys lys ala

271 AAA TCG AAG AAG CTG TCT GCC GCT AAG ACG GAA TAT CAA AAG CGT  
 lys ser lys lys leu ser ala ala lys thr glu tyr gln lys arg

316 TCT GCT GTT GTG TCA TCT TTA AAA GTC ACA GCC GAT GAA TCC CAG  
 ser ala val val ser ser leu lys val thr ala asp glu ser gln

361 CAA GAT GTC CTA AAA TAC TTG AAC ACC CAG AAA GAT AAA GCA AAT  
 gln asp val leu lys tyr leu asn thr gln lys asp lys gly asn

406 GCA GAC CAA ATT CAT TCT TAT TAT GTG GTG AAC GCG ATT GCT GTT  
 ala asp gln ile his ser tyr tyr val val asn gly ile ala val

451 CAT GCC TCA AAA GAG GTT ATG GAA AAA GTG GTG CAG TTT CCC GAA  
 his ala ser lys glu val met glu lys val val gln phe pro glu

## FIG. 10-2

496 GTG GAA AAG GTG CTT CCT AAT GAG AAA CCG CAG CTT TTT AAG TCA  
 val glu lys val leu pro asn glu lys arg gln leu phe lys ser  
 541 TCC TCC CCA TTT AAT ATG AAA AAA GCA CAG AAA GCT ATT AAA GCA  
 ser ser pro phe asn met lys lys ala gln lys ala ile lys ala  
 586 ACT GAC GGT GTG GAA TGG AAT GTA GAC CAA <sup>ClaI</sup> ATC GAT GGC CCA AAA  
 thr asp gly val glu trp asn val asp gln ile asp ala pro lys  
 631 GCT TGG GCA CTT GGA TAT GAT GGA ACT GGC ACG GTT GTT GCG TCC  
 ala trp ala leu gly tyr asp gly thr gly thr val val ala ser  
 676 ATT GAT ACC GGG GTG GAA TGG AAT CAT CCG GCA TTA AAA GAG AAA  
 ile asp thr gly val glu trp asn his pro ala leu lys glu lys  
 721 TAT CGC GGA TAT AAT CCG GAA AAT CCT AAT GAG CCT GAA AAT GAA  
 tyr arg gly tyr asn pro glu asn pro asn glu pro glu asn glu  
 766 ATG AAC TGG TAT GAT GCC GTA GCA GGC GAG GCA AGC CCT TAT GAT  
 met asn trp tyr asp ala val ala gly glu ala ser pro tyr asp  
 811 GAT TTG GCT CAT GGA ACC CAC GTG ACA GGC ACG ATG GTG GGC TCT  
 asp leu ala his gly thr his val thr gly thr met val gly ser  
 856 GAA CCT GAT GGA ACA AAT CAA ATC GGT GTA GCA CCT GGC GCA AAA  
 glu pro asp gly thr asn gln ile gly val ala pro gly ala lys  
 901 TGG ATT GCT GTT AAA GCG TTC TCT GAA GAT GGC GGC ACT GAT GCT  
 trp ile ala val lys ala phe ser glu asp gly gly thr asp ala  
 946 GAC ATT TTG GAA GCT GGT GAA TGG GTT TTA GCA CCA AAG GAC GCG  
 asp ile leu glu ala gly glu trp val leu ala pro lys asp ala  
 991 GAA GGA AAT CCC CAC CCG GAA ATG GCT CCT GAT GTT GTC AAT AAC  
 glu gly asn pro his pro glu met ala pro asp val val asn asn

## FIG. 10-3

1036 TCA TGG GGA GGG GGC TCT GGA CTT GAT GAA TGG TAC AGA GAC ATG  
 ser trp gly gly gly ser gly leu asp glu trp tyr arg asp met  
 1081 GTC AAT GCC TGG CGT TCG GCC GAT ATT TTC CCT GAG TTT TCA GCG  
 val asn ala trp arg ser ala asp ile phe pro glu phe ser ala  
 1126 GGG AAT ACC GAT CTC TTT ATT CCC GGC GGG CCT GGT TCT ATC GCA  
 gly asn thr asp leu phe ile pro gly gly pro gly ser ile ala  
 1171 AAT CCG GCA AAC TAT CCA GAA TCG TTT GCA ACT GGA GCG ACT GAT  
 asn pro ala asn tyr pro glu ser phe ala thr gly ala thr asp  
 1216 ATC AAT AAA AAG CTC GCT GAC TTT TCT CTT CAA GGG CCA TCT CCA  
 ile asn lys lys leu ala asp phe ser leu gln gly pro ser pro  
 1261 TAT GAT GAA ATA AAG CCG GAA ATA TCT GCA CCG GGC GTT AAT ATT  
 tyr asp glu ile lys pro glu ile ser ala pro gly val asn ile  
 1306 CGT TCA TCG GTT CCC GGT CAG ACA TAT GAG GAT GGT TGG GAC GGC  
 arg ser ser val pro gly gln thr tyr glu asp gly trp asp gly  
 1351 ACA TCA ATG GCA GGG CCG CAT GTA TCC GCT GTT GCT GCA CTG CTG  
 thr ser met ala gly pro his val ser ala val ala ala leu leu  
 1396 AAA CAG GCG AAT GCC TCA CTT TCT GTT GAT GAG ATG GAG GAT ATA  
 lys gln ala asn ala ser leu ser val asp glu met glu asp ile  
 1441 TTA ACC AGC ACG GCT GAA CCG CTC ACG GAT TCA ACA TTT CCT GAT  
 leu thr ser thr ala glu pro leu thr asp ser thr phe pro asp  
 1486 TCA CCG AAT AAC GGA TAT GGC CAT GGT CTG GTG AAT GCT TTT GAT  
 ser pro asn asn gly tyr gly his gly leu val asn ala phe asp  
 1531 GCT GTA TCC GCT GTT ACA GAT GGA TTA GGG AAA GCG GAA GGA CAA  
 ala val ser ala val thr asp gly leu gly lys ala glu gly gln  
 1576 GTT TCT GTA GAG GGG GAT GAC CAA GAG CCT CCT GTC TAT CAG CAT  
 val ser val glu gly asp asp gln glu-pro pro val tyr gln his

## FIG. 10-4

1621 GAG AAA GTA ACT GAA GCT TAT GAA GGT GGC AGC CTA CCA CTG ACT  
 glu lys val thr leu ala tyr glu gly gly ser leu pro leu thr  
 1666 TTG ACA GCT GAA GAC AAT GTG AGT GTG ACA TCT GTA AAG CTG TCC  
 leu thr ala glu asp asn val ser val thr ser val lys leu ser  
 1711 TAC AAG CTT GAT CAA GGT GAA TGG ACA GAA ATA ACG GCT AAA CGA  
 tyr lys leu asp gln gly glu trp thr glu ile thr ala lys arg  
 1756 ATC AGC GGT GAT CAT CTA AAA GGA ACG TAT CAG GCA GAG ATC CCA  
 ile ser gly asp his leu lys gly thr tyr gln ala glu ile pro  
 1801 GAT ATA AAA GGA ACT AAA CTA AGC TAT AAG TGG ATG ATT CAC GAT  
 asp ile lys gly thr lys leu ser tyr lys trp met ile his asp  
 1846 TTT GGC GGT CAT GTC GTT TCG TCT GAC GTA TAC GAT GTA ACA GTG  
 phe gly gly his val val ser ser asp val tyr asp val thr val  
 1891 AAA CCA AGC ATC ACG GCG GGA TAT AAG CAG GAC TTT GAA ACT GCA  
 lys pro ser ile thr ala gly tyr lys gln asp phe glu thr ala  
 1936 CCC GGC GGC TGG GTT GCG AGC GGA ACA AAT AAT AAC TGG GAA TGG  
 pro gly gly trp val ala ser gly thr asn asn asn trp glu trp  
 1981 GGA GTT CCG TCA ACT GGC CCA AAT ACA GCA GCA TCC GGA GAA AAA  
 gly val pro ser thr gly pro asn thr ala ala ser gly glu lys  
 2026 GTA TAT GGA ACG AAT TTG ACA GAA ATT ATG CCA ACT CAG CAA ACA  
 val tyr gly thr asn leu thr glu ile met pro thr gln gln thr  
 2071 TGA ACCTTGTTATGCTCTCTATTAAAGCACCTGATTCAGGAAGTCTGTTCTTCAATT  
 OPA  
 TAAAAGCTGGCACAATTTAGAGGATGATTTTGATTACGGCTACGTTTTTGTTCCTCCGGA  
 AGGTGAAAAAATTGAGAGGCTGGTGTCTATACGGAAGCTCAAGCTGGACGGACGAG  
 AATGTTATCGGCTTATAAG



	1	2	3	4	5	6	7	8	9	10	
	Val	- Thr	- Asn	- Asp	- Val	- Phe	- Asn	- Asn	- Ile	- Gln	-
	(4)	(4)	(2)	(2)	(4)	(2)	(2)	(2)	(3)	(2)	
5'	- CTG	- ACA	- AAC	- GAC	- GTG	- TTT	- AAC	- AAC	- ATC	- CAG	-

	11	12	13	14	15	
	Tyr	- Trp	- Ala	- Asn	- Gln	
	(2)	(1)	(4)	(2)	(2)	
	TAT	- TGG	- GCA	- AAC	- CAG	- 3'

FIG. 11a

1	2	3	4	5	6	7	8	9	10
Ala -	Thr -	Val -	Gln -	Leu -	Ser -	Ile -	Lys -	Tyr -	Pro -
(4)	(4)	(4)	(2)	(6)	(6)	(3)	(2)	(2)	(4)
5' - GCA -	ACA -	GTT -	CAA -	CTT -	TCA -	ATC -	AAA -	TAT -	CCG -

11	12	13	14	15	16	17	18	19	20
Asn -	Thr -	Ser -	(Cys)-(Thr)-	Tyr -	(Gly)-	Asn -	Thr -	Gly -	
(2)	(4)	(6)	(2)	(4)	(2)	(4)	(2)	(4)	(4)
AAC -	ACA -	TCA -	TGC -	ACA -	TAT -	GGC -	AAC -	ACA -	GGC -

21	22	23	24	25	26	27	28	29	30
Phe -	Leu -	Val -	Asn -	Pro		-(Thr)-	Val -	Val -	Thr -
(2)	(6)	(4)	(2)	(4)		(4)	(4)	(4)	(4)
TTT -	CTT -	GTT -	AAC -	CCG -	3'				

31  
Ala  
(4)

FIG. 11b

1	2	3	4	5	6	7	8	9	10
Thr -	Thr -	Asn -	Ser -	Ser -	Ser -	Pro -	Val -	Gly -	Leu -
(4)	(4)	(2)	(6)	(6)	(6)	(4)	(4)	(4)	(6)
11	12	13	14	15	16	17	18	19	20
Ser -	Ser -	Ser -	Val -	Thr -	Gly -	Phe -	Pro -	Cys -	Asp -
(6)	(6)	(6)	(4)	(4)	(4)	(2)	(4)	(2)	(2)
			3' - TGT - CCG - AAA - GGC - ACG - CTG -						
21	22	23	24	25	26	27	28	29	30
Lys -	Thr -	Phe -	Gly -	Thr -	Met -	Trp -	Ser -	Asp -	Thr -
(2)	(4)	(2)	(4)	(4)	(1)	(1)	(6)	(2)	(4)
TTT - TGT - AAA - CCG - TGT - TAC - ACC - 5'									
31	32	33	34	35	36				
Lys -	Pro -	Ile -	Asn -	Ser -	Arg				
(2)	(4)	(3)	(2)	(6)	(6)				

FIG. 11c

FIG. 13b





FIG. 13c



**FIG. 14-1**

475 ATA ACC GCC GCG CCG GGC CGC AAT GGT TCG TCA TAT CCG TAC GGT  
 ile thr ala pro gly arg asn gly ser ser tyr pro tyr gly  
 520 ACT TAT TCA GGC ACG ATG TTT TAC TCC GTC AAA GGA TGG ACG GAA  
 thr tyr ser gly thr met phe tyr ser val lys gly trp thr glu  
 565 AGC AAA GAC ACC AAC TAT GAT TAC GGA GCT ATT AAA TTA AAC GGT  
 ser lys asp thr asn tyr asp tyr gly ala ile lys leu asn gly  
 610 TCT CCT GGA AAC ACG GTT GGC TGG TAC GGC TAC CCG ACT ACA AAC  
 ser pro gly asn thr val gly trp tyr gly tyr arg thr thr asn  
 655 AGC AGC AGT CCC GTG GGC CTT TCC TCG TCA GTG ACA GGA TTC CCA  
 ser ser ser pro val gly leu ser ser ser val thr gly phe pro  
 700 TGT GAC AAA ACC TTT GGC ACG ATG TGG TCT GAT ACA AAG CCG ATT  
 cys asp lys thr phe gly thr met trp ser asp thr lys pro ile  
 745 GGC TCC GCT GAA ACG TAT AAG CTG ACC TAT ACA ACC GAT ACG TAC  
 arg ser ala glu thr tyr lys leu thr tyr thr thr asp thr tyr  
 790 GGC TGC CAA AGC GGC TCG CCT GTT TAT CGA AAC TAC AGT GAT ACA  
 gly cys gln ser gly ser pro val tyr arg asn tyr ser asp thr  
 835 GGG CAG ACA GCT ATT GCC ATT CAC ACG AAC GGA TCG TCA TAT  
 gly gln thr ala ile ala ile his thr asn gly gly ser ser tyr  
 880 AAC TTG GGA ACA AAG GTG ACG AAC GAT GTA TTC AAC AAT ATT CAA  
 asn leu gly thr arg val thr asn asp val phe asn asn ile gln  
 925 TAT TGG GCA AAT CAA TAA ATACAGCAAACTAGCCATATTCATGTCTAT  
 tyr trp ala asn gln OCH

T90

FIG. 14-2

